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ABSTRACT 
The human body is host to a complex community of microorganisms collectively 
known as the microbiota. Specifically, the gastrointestinal tract harbors trillions of 
bacteria with important roles in host health. The gut microbiota can play a critical role in 
preventing invading microbes from persistently colonizing the gastrointestinal tract, a 
phenomenon known as colonization resistance. Perturbations, such as antibiotic 
treatments, which change the structure of the gut microbiota, may in turn alter 
colonization resistance to pathogenic microbes. Epidemiological studies demonstrate 
that antibiotic use is a major risk factor for acquiring a Clostridium difficile infection 
(CDI), which is the leading nosocomial infection in the United States. I hypothesized that 
multiple bacterial populations contribute to the inhibition of C. difficile colonization. To 
test this hypothesis, I investigated the role of the gut microbiota in colonization 
resistance against C. difficile in both humans and mice. Across both hosts, I 
demonstrated that a loss in Lachnospiraceae, Ruminococcaceae, 
Porphyromonadaceae, Bacteroides, and Alistipes were highly correlated with loss of 
  xi 
colonization resistance. Using mathematical modeling of microbiota abundance data, I 
showed that the microbiota was a powerful indicator of disease state and could be used 
to accurately predict levels of C. difficile colonization, effectively measuring the 
microbiota’s level of resistance against this pathogen. My results demonstrated the 
importance of the microbiota as a whole in conferring colonization resistance. These 
studies provide important insight into the relationships between members of the 
microbiota and C. difficile and further define a consortia of bacteria from which efficient 
probiotic therapies can be designed.  
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Chapter I 
Introduction 
 
 
The Human Microbiota 
The human body is host to a diverse set of microorganisms, comprised of 
bacteria, viruses, protozoa, fungi, and eukaryotes, known as the microbiota. The most 
widely studied of these microorganisms are bacteria, which outnumber our own cells 
10-fold (1) and collectively have over 100 times the number of human genes (2). The 
majority of these bacteria reside throughout the gastrointestinal (GI) tract, reaching 
upwards of 100 trillion bacteria cells (3). These bacteria have adapted their lifestyle to 
the gut environment. The structure of these communities, referring to which bacterial 
species are present and their abundance, develops with its human host beginning at 
birth (4-10). The intimate relationship between humans and their associated microbes 
has made the microbiota an integral part in normal host function.  
 
Defining the “Healthy” Microbiota 
Previously, characterization of the microbiota was limited because the laboratory 
growth conditions for most gut bacteria are yet unknown, and consequently only a 
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subset of the microbiota could be characterized. With the advent of next-generation 
sequencing came the ability not only to uncover uncultivable bacteria but also the 
structure of the microbiota in a massively parallelized manner. Huge efforts have been 
taken to define the “healthy” microbiota structure both in humans (11-16) and in mice 
(17-19), which are often used for in vivo models. These studies are important in 
providing a baseline understanding of the microbiota in a healthy state. Cataloguing the 
healthy human gut microbiota has revealed that there is no “core” bacterial community 
defined by a subset of bacterial members (20). In a cohort of 154 individuals there was 
no bacterial species that could be found in the microbiota of every subject, underlining a 
high level of inter-individual taxonomic diversity across the human population (20). 
There are, however, proposed “core” functions represented by the microbiota (15, 20), 
which have been described through metagenomic sequencing of the human gut (21). 
Three broader gut “community types” called enterotypes have been described to 
categorize the microbiotas of healthy individuals (16). These enterotypes are defined by 
a predominance of Bacteroides, Prevotella, or Ruminococcus (16). These community 
types are likely not discrete groupings but rather exist on a gradient. Using multiple 
mathematical approaches to define these microbiota types, continuous gradients of 
bacterial abundances have been observed within body sites as well as bi- and multi-
modal abundance distributions (22). Another study of community types across human 
body sites has shown that community types are distinguishable not simply by the most 
predominant bacterial population, but rather by more complex assemblages of bacteria 
likely shaped by overall life history factors (11). In the human gut microbiota, the 
Bacteroidetes and Firmicutes bacterial phyla dominate overall with a higher proportion 
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of Bacteroidetes (19, 23). This is also similar to what is observed in mice. Comparison 
of the human and mouse gut microbiota at higher taxonomic levels shows strong 
overlap in community structure. Major differences between these hosts are observed at 
the genus level, where only 15% of mouse genera were also found in humans (19). 
Thus, the definition of a “healthy microbiota” covers a wider scope of community 
structures. Broadly we can discern healthy patterns across the human population, but at 
refined taxonomic levels, healthy is best assessed on an individual basis. These 
observations are important considerations when studying the microbiota during disease 
states and developing microbiota-based therapies.  
 
The Gastrointestinal Environment 
Not only are there inter-individual differences found in humans, but there is also 
intra-individual variation in the structure of the microbiota across and even within body 
sites (14). The gastrointestingal tract, comprised of the stomach, small intestine, cecum, 
appendix (in humans), large intestine, and rectum, represents diverse environments, 
along which are several environmental changes (Figure 1.1). Microorganisms, including 
external pathogens, entering the body orally and traveling through the gastrointestinal 
tract must be able to survive these extreme environmental changes. To name a few, pH 
and oxygen gradients exist along the gut, starting with the acidic and aerobic stomach 
to the more neutral and anaerobic environment of the colon. Additionally there are shifts 
in general nutrient availability as the host and resident microbes break down diet 
components. For example, limited levels of short chain fatty acids (SCFAs) are 
observed in the small intestine, which increases closer towards the colon (24-26).  
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FIGURE 1.1 Environmental changes throughout the gastrointestinal tract 
The specific ranges of bacterial load and pH levels throughout the GI tract are shown 
(31). In mice, the GI tract includes a functioning cecum. While in humans, the cecum 
represents the transition from the small to large intestine. Humans additionally have an 
appendix, which has no known function, but may serve as a reservoir for resident 
bacteria.  
 
Image adapted from Mowat A.M. and Agace W.W. 2014. Nature. Rev. Immunol. 14:667, See ref 
(32) 
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Consequently, these unique environments along the gastrointestinal tract harbor 
different amounts of total bacteria with varying compositions.  Within the colon exist 
further microenvironments. The lumen of the colon is anaerobic. Closer to the epithelial 
layer there is a gradual increase in oxygen creating a microoxic environment (27). This 
radial oxygen gradient contributes to the segregation of oxygen tolerant and intolerant 
bacteria (27). An outer and largely sterile inner layer of host mucus protects the 
epithelium acting as a physical barrier to prevent bacterial proximity and translocation 
(28-30). These diverse conditions create a number of habitats in the gut for bacteria to 
reside and also represent environmental challenges for orally ingested microorganisms 
traveling through the gut. 
 
The Microbiota’s Dual Role in Human Health and Disease 
Many of the resident microbiota have a mutualistic relationship with their host, 
meaning that both the microbiota and the host benefit from this relationship. In fact, the 
microbiota has essential roles in human health. Specifically within the gut, the 
microbiota functions in digestion of host-indigestible carbohydrates (2, 3), synthesis of 
vitamins (2), maturation of the immune system (33, 34), regulation of immune 
homeostasis (34-36), and defense against invasive pathogens (37-40). When the 
microbiota is significantly perturbed, it can result in a state of dysbiosis, which describes 
a destabilized deviation of the bacterial community’s structure from its healthy baseline. 
Dysbiosis has been implicated in a number of diseases including inflammatory bowel 
disease (41-44), metabolic disorders (45, 46), obesity (19, 47), colorectal cancer (48-
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51), and several gastrointestinal infections (52-56). Thus, maintaining a diverse, stable 
microbiota is critical for human health. 
 
The Microbiota Confers Colonization Resistance 
Of the many beneficial roles of a healthy gut microbiota, the ability by the 
indigenous microbiota to protect against invasive pathogens from persistently colonizing 
the gastrointestinal tract is called colonization resistance. The microbiota is known to 
play a significant role in colonization resistance against several GI bacterial pathogens, 
including VRE (40, 57-60), Salmonella enterica serovar Typhimurium (54, 61-66), 
Escherichia coli (67-75), and Clostridium difficile (52, 58, 76-80). In the case of C. 
difficile infections, epidemiological data has shown that antibiotic use is one of the major 
risk factors (81-86). Antibiotics alter the normal bacterial structure of the microbiota 
towards a state of dysbiosis. In this state, the host is susceptible to colonization and 
infection by C. difficile. It is unknown what precise changes to the microbiota structure 
and function are responsible for the loss in colonization resistance against C. difficile.  
 
Clostridium difficile Infections 
Epidemiology 
 C. difficile is an emerging pathogen in the United States, recently surpassing 
MRSA as the most reported nosocomial infection. It is estimated there were 450,000 C. 
difficile infections (CDI) and 29,000 related deaths in 2011 (87). As a result, the 
associated health care costs are estimated in excess of $1 billion annually. Individuals 
colonized with C. difficile may be asymptomatic (approximately 3-5% of healthy adult 
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population) or experience a range of CDI severity from mild and moderate disease with 
diarrhea and pseudomembrane colitis to severe infection with toxic megacolon and 
sometimes death (81). Epidemiological studies identify antibiotic use, age over 65, 
prolonged stay at a health care-associated setting, comorbidities, immunocompromised 
state, and proton pump inhibitors as major risk factors for CDI (81-85, 88-90). 
Interestingly, many of these risk factors also have effects on the stability and structure 
of the microbiota (88, 89, 91, 92). Furthermore, in the environment C. difficile exists in 
its highly resistant spore form, which makes it difficult to eradicate. This is highly 
problematic in health care-associated settings, where an individual may be exposed to 
several CDI risk factors or perturbations to the microbiota and where subsequently an 
estimated 66% of all CDI-onset occurs (87). 
 
C. difficile Colonization and Infection 
 The dynamics of C. difficile colonization and infection is an area of great interest. 
When the transmissive spore form of C. difficile has been orally ingested, spores safely 
travel through the acidic stomach environment to the small intestine (Figure 1.1). Here 
germination factors, including primary bile acids such as taurocholate and the amino 
acid glycine, induce germination of spores to vegetative cells (79, 93). These vegetative 
cells travel to the cecum (of mice) and colon in search of resources for growth. In a non-
susceptible state containing an intact microbiota, C. difficile is outcompeted for these 
resources. In a susceptible state containing a dysbiotic microbiota these resources are 
more readily available (65, 94). The earliest observations of CDI at 6 hours post 
infection reveal C. difficile vegetative cells in the cecum of cefoperazone-treated (79). 
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Approximately 24 hours later C. difficile spores are largely detectable in the cecum, 
colon, and stool. This increase in spore production towards the distal gastrointestinal 
tract could be important for transmission of C. difficile. Sporulation coincides with 
production of its two main toxins, the enterotoxin A and the cytotoxin B (79). These 
glucosylating toxins disrupt Rho family GTPases, causing actin depolymerization, loss 
of cell architecture, cell death, and breakdown of epithelial barrier function (95). There is 
a third known toxin, the cytolethal distending toxin or binary toxin (CDTa and CDTb), 
whose role in the pathogenesis of CDI is unclear. Epidemiological studies suggest that it 
enhances pathogenesis, as humans infected with a CDT carrying strain have a 60% 
increase in fatality (96). These toxins increase gut inflammation and induce the 
histopathological changes to the large intestine.  
 
Current Treatment Courses 
Standard treatment for CDI includes antibiotic regimens of metronidazole or 
vancomycin, which inhibit C. difficile but also continue to perturb the microbiota 
structure. In as many as 25-30% of cases, individuals will have recurrent CDI following 
clearance of initial infection (97-100). Treatments for CDI clearly require consideration 
of its effect on the microbiota and should aim to restore an overall healthy microbiota 
structure. In cases of recurrent CDI, fecal microbiota treatment (FMT) has been 
implemented with increasing use. This requires the collection of stool sample from a 
healthy donor, preferably a significant other or maternal-line first degree relative, who 
are likely to harbor more similar microbiota structures (101, 102). Stool is screened for a 
variety of pathogens (101) and prepared for transplant into the recipient via enema, 
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colonoscopy, or nasogastric tube. Following successful transmission of the donor 
bacterial community, the microbiota of the recipient shifts towards a structure more 
similar to the donor’s (103, 104). In a microbiota survey of 14 individuals before and 
after receiving FMT, the level of Bacteroidetes increased, Proteobacteria decreased, 
and diversity increased (103), which are all characteristic of “healthy” human gut 
microbiotas. A systematic review of FMT for CDI reported that the efficacy of FMT is 
90% (105). The success of this treatment emphasizes the importance of the microbiota 
as a whole in protection from C. difficile. That we do not fully understand the mechanism 
behind this treatment highlights the need for a greater understanding of the interactions 
between the microbiota and C. difficile. 
 
The Microbiota and C. difficile 
Previous work characterizing the microbiota of humans and mice in the context of 
CDI provide a glimpse into potentially protective and alternatively susceptible 
community structures (Table 1.1). In humans, fecal samples taken from patients who 
subsequently developed CDI have been compared to age and sex matched controls 
(106). The microbiota of patients with CDI have increased levels of Enterococcaceae 
and decreased Clostridiales Incertae Sedis XI and Bacteroidaceae compared with the 
matched controls. Additionally, decreased diversity is seen compared with controls. 
Individuals with recurrent CDI have an even greater drop in the diversity of their 
microbiota compared to individuals with an initial CDI episode (107). 
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Bacteria Associated with  
Resistance or Susceptibility to CDI 
Bacteria Host Potential Role  References 
Bacteroidaceae Human, Mouse Resistance 18, 78 
Bacteroidaceae (Bacteroides 
thetaiotaomicron) Mouse Susceptibility 65 
Porphyromonadaceae, e.g. 
Barnesiella 
Human, 
Mouse Resistance 18, 76, 78 
Lachnospiraceae, e.g. Blautia, 
Clostridium clostridiaforme, 
Clostridium scindens 
Human, 
Mouse Resistance 
18, 52, 76-78, 
116, 143 
Ruminococcaceae Mouse Resistance 78 
Clostridiales Incertae Sedis XI Human Resistance 18 
Lactobacillaceae Mouse Susceptibility 52, 78, 80 
Enterococcaceae Human Susceptibility 18, 143 
Proteobacteria Human, Mouse Susceptibility 52, 76-78 
Enterobacteriaceae Mouse Susceptibility 52, 76-78 
Pseudomonadaceae Mouse Susceptibility 52 
Verrucomicrobiaceae 
(Akkermansia) Mouse Susceptibility 78 
Verrucomicrobiaceae 
(Akkermansia) Mouse Resistance 143 
Erysipelotrichaceae 
(Coprobacillus) Mouse 
Resistance 
(indirect) 143 
 
TABLE 1.1 Bacteria associated with resistance or susceptibility to CDI 
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 These human studies however lack the baseline healthy state of the microbiota 
of these individuals. Murine models of CDI have been utilized because we can control 
for specific changes that occur before and after antibiotic perturbations and the 
introduction of C. difficile. The first model of CDI in conventional mice that more closely 
mimicked human disease used a 5 antibiotic cocktail made of gentamicin, kanamycin, 
colistin, metronidazole, and vancomycin in water followed by a single intraperitoneal 
injection of clindamycin prior to C. difficile challenge (108). When challenged with C. 
difficile vegetative cells, mice either displayed severe signs of CDI or appeared healthy 
with no significant weight loss (52). The microbiota of healthier mice had a high 
abundance of Lachnospiraceae, similar to control mice without antibiotics, while sick 
mice contained mostly Enterobacteriaceae, similar to antibiotic treated mice.  
Since the introduction of this initial mouse model, other antibiotic regimens have 
been used to assess how they alter the gut microbiota and ultimately colonization 
resistance. Across these different antibiotic perturbations, similar microbial patterns 
have been observed in both C. difficile susceptible and resistant communities. Ten days 
of cefoperazone (a third generation cephalosporin) in the drinking water with or without 
a follow-up clindamycin injection resulted in Lactobacillaceae dominance of the 
microbiota and susceptibility to C. difficile. A single clindamycin injection has also shown 
to induce susceptibility and a high prevalence of Enterobacteriaceae (109). 
Enterobacteriaceae along with Verrucomicrobiaceae were increased in the gut 
microbiota of mice treated with tigecycline, which C. difficile successfully colonized (78). 
Across these studies, comparison of C. difficile susceptible communities with untreated 
controls often correlates with a significant loss in Clostridiales (e.g. Lachnospiraceae 
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and Ruminococcaceae) and Bacteroidales with a loss in colonization resistance (Table 
1.1). Direct evidence of a Lachnospiraceae isolate’s contribution to resistance to C. 
difficile was further tested through monocolonization of germfree mice. These mice have 
increased resistance to C. difficile, compared with E. coli mono-colonization, which had 
no effect on C. difficile levels (77). 
 
Mechanisms of C. difficile Colonization Resistance by the Microbiota 
 The mechanisms of colonization resistance by the gut microbiota against C. 
difficile are yet to be uncovered. Moreover it is not fully appreciated at what stages of C. 
difficile infection these protective functions act on. It is known that mice with an intact 
normal microbiota are resistant to C. difficile colonization. An examination of the murine 
gut metabolites before and after cefoperazone-induced susceptibility to C. difficile, as 
well as after challenge with C. difficile, highlighted an important role for the microbiota in 
limiting resources necessary for C. difficile spore germination and outgrowth (80). 
Following antibiotic perturbation, there is a shift from secondary to primary bile acids in 
the gut, specifically an increase in the availability of primary bile acid taurocholate, a 
germinant for C. difficile spores. This leads to the hypothesis that the gut microbiota can 
indirectly inhibit germination of C. difficile spores ingested by the host. However, recent 
ex-vivo and in vivo experiments show that C. difficile spores are able to germinate in the 
distal small intestine of untreated mice (79, 93). Thus additional mechanisms of 
colonization resistance are necessary for inhibition of subsequent stages of C. difficile’s 
colonization. 
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FIGURE 1.2 Mechanisms of colonization resistance by the microbiota against C. 
difficile 
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 Competition for nutrients plays a significant role by limiting growth of vegetative 
C. difficile (Figure 1.2). Early studies in a continuous flow culture model of the cecal 
mouse microbiota have shown that C. difficile utilizes glucose, N-acetylglucosamine, 
and N-acetylneuraminic acid, although it does not contain the hydrolytic enzymes 
necessary to free these monosaccharides which are largely present in mucin (110). 
Furthermore, in the presence of the microbiota C. difficile is outcompeted for these 
resources and its growth is suppressed (65, 110). Sialic acids and succinate are two 
additional nutrient sources for C. difficile. In the presence of the indigenous microbiota, 
these resources are scarcely free in the milieu. However, following antibiotic treatment 
or polyethylene glycol treatment to significantly alter the microbiota, these nutrients are 
readily available to support C. difficile’s growth (65, 94). Depending on the 
environmental nutrients available to C. difficile, i.e., a polysaccharide rich versus 
deficient host diet, it can adapt by metabolizing succinate or sialic acids in host mucin, 
respectively (94). In a previous metabolomic survey, following cefoperazone treatment 
the levels of sugar alcohols and carbohydrates favorable for C. difficile outgrowth, 
including sorbitol, mannitol, raffinose, stachyose, and fructose also increased, creating 
an unclaimed pool of nutrients for C. difficile’s growth (80).  
 Microbiota products and metabolic byproducts have been shown to inhibit C. 
difficile growth. Several microbiota-produced bacteriocins in the gut have been 
demonstrated to have anti-C. difficile activity with minimal consequences to the overall 
structure of the microbiota. For example, indigenous Bacillus thuringiensis produces a 
bacteriocin named thuricin CD with a narrow target range that includes C. difficile (111). 
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R-type bacteriocins, similar to those found in Pseudomonas aeruginosa, similarly have 
anti-C. difficile activity (112). These can be modified to further increase specificity for 
fluoroquinolone-resistant BI/NAP1/027 strains of C. difficile (113), which have emerged 
in several outbreaks and have been attributed with more severe infection (114-116). 
Additionally, the baseline gut microbiota (prior to antibiotics) has high levels of 
deoxycholate (80, 117), which is a secondary bile acid made by microbiota members 
that inhibits C. difficile growth (118). For example, Clostridium scindens, a 
Lachnospiraceae, has enzymes that are able to biotransform cholate into deoxycholate, 
which inhibits C. difficile growth in a dose-dependent manner (117-119).  
 
The Microbiota Stimulates Host Immune Defenses 
 The microbiota also indirectly inhibits C. difficile’s colonization and infection 
through stimulation of the immune system. Neutrophils are critical innate immune cells 
in early response to CDI (120, 121). Stimulation of NOD1 by C. difficile ligands mediates 
neutrophil recruitment through the production of the CXC-chemokine ligand 1 (CXCL1) 
(122). CXCL1 production by epithelial cells requires the secreted cytokine IL-1β, which 
is stimulated in part by the indigenous microbiota translocated across the epithelium 
during infection with toxigenic C. difficile (123). Innate immune activation via microbiota 
signaling through toll-like receptors (TLRs) and the MyD88 pathway is important for 
protection against severe CDI (120, 124). MyD88 deficient mice have a significant 1000-
fold reduction in expression of colonic CXCL1 compared with wild-type (WT) mice (120). 
Subsequently, these mice also have significantly less neutrophil and monocyte 
recruitment to the colonic lamina propria.  
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The significance of microbiota stimulation through several TLRs has been 
examined. TLR5 stimulation by flagellin treatments (using Salmonella enterica serovar 
Typhimurium-derived flagellin) protected against mortality (125) using the Chen et al. 
CDI murine model (108). In the absence of TLR5, this protection was ablated. These 
flagellin treatments significantly reduced C. difficile levels and pathology in the cecum 
and colon, showing the potential influence of other microbiota members in stimulating 
the immune system to protect against CDI. TLR4 deficient mice have more severe 
disease than WT or TLR2 deficient mice (126) using the same model of CDI (108). That 
these TLRs have differential roles during CDI may not be surprising given their 
recognition of different bacterial cell wall components (127).  Importantly, TLR4 deficient 
mice are not susceptible to CDI without prior antibiotic treatment (126), emphasizing the 
primary role of the microbiota in C. difficile defense.  
 Innate defenses against other gastrointestinal pathogens suggest potential 
mechanisms that are also active against C. difficile. Antimicrobial peptides (AMPs), 
such as RegIIIγ, are important in defense against several gastrointestinal pathogens 
including Citrobacter rodentium (128, 129), Listeria monocytogenes (130-132), 
Salmonella enterica serovar Typhimurium (129), Staphylococcus aureus (132), and 
Vancomycin-Resistant Enterococci (VRE) (133). Epithelial cells express these AMPs via 
microbiota signaling through MyD88 (134-136). Although no change in expression of 
RegIIIγ is detected following cefoperazone treatment of mice (52), other perturbations to 
the microbiota can have different effects on AMP levels (137) .  
Beyond acute infections, the microbiota also influences adaptive immune 
responses to CDI. For example, IgA, specifically secretory IgA (sIgA) in the gut, is 
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important in mucosal immunity during gastrointestinal infections, as mice lacking sIgA 
have increased bacterial epithelial translocation (34). Interestingly, secretory IgA 
response is dependent on the resident microbiota and is adaptive to the changing 
microbiota composition (138, 139). Secretory IgA has been shown to contribute to 
protection against CDI, likely by providing additional protection to the epithelial barrier 
(140). However mice lacking the polymeric immunoglobulin receptor to transcytose 
antibodies across the epithelium reveal that though sIgA responses may contribute to 
protection, they are not required (140). Studies investigating the role of serum IgA and 
IgG against C. difficile toxins have debated the importance anti-toxin A versus anti-toxin 
B antibodies. For instance, in a case-control study of two geographically distinct 
cohorts, IgA levels against only toxin B were increased in cases versus controls (141). 
However, human monoclonal antibodies against both toxins A and B have been shown 
to significantly reduce CDI recurrence rate (142). Overall, the significance of the 
adaptive immune response in CDI is not completely understood, and more work is 
necessary to elucidate the role of the microbiota in shaping these responses against 
CDI. 
 
Studying Colonization Resistance as a Community Effect 
 The processes that determine C. difficile’s colonization are multilayered and 
involve a complex network of bacteria each with varying influence over C. difficile’s fate. 
Total colonization resistance cannot be accurately measured in the context of one 
species’ effect on another. Studies using multi-species probiotics against murine CDI 
show the synergistic protective effect of a bacterial consortium over its individual 
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members (117, 143). In studying the microbiota in health and disease, mathematical 
modeling is a useful tool to measure the importance of multiple factors in determining 
disease outcome. For example, a model built using data on a patient’s microbiota 
structure accurately predicts psoriasis diagnosis (144). Mathematical modeling of a 
murine CDI model was also largely successful in predicting microbiota dynamics over 
time (145). These tools provide a potential means to predict the level of colonization 
resistance based on the microbiota structure. This would significantly improve CDI risk 
assessments and inform the design of multi-species probiotics. 
 
Summary and Chapter Outline 
 The microbiota plays an integral role in colonization resistance against pathogen 
invasion. Alterations to the structure of the microbiota can result in host susceptibility to 
C. difficile. It is poorly understood what microbiota changes are necessary to occur for 
this loss in colonization resistance. The focus of this dissertation is to determine which 
members of the microbiota significantly contribute to colonization resistance and 
characterize C. difficile’s interaction with the microbiota.  
 In Chapter II, we characterize the microbiotas of human subjects with and without 
CDI. The microbiota of individuals with CDI had increased levels of Enterococcus and 
Escherichia coli, while control microbiotas contained higher levels of Bacteroides. Using 
information about the structure of the microbiota, we improve accuracy of models 
predicting C. difficile diagnosis based on patients’ epidemiological data alone. This 
shows the impact of the microbiota as a whole in assessing C. difficile infection status.  
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 In Chapter III we examine the effects of antibiotic perturbation on the murine gut 
microbiota structure and subsequent colonization resistance level against C. difficile. 
Several types and degrees of antibiotic manipulations were used to narrow in on 
bacteria responsible for the levels of C. difficile observed following challenge of these 
communities. Escherichia, similarly to what is observed in humans, has a positive 
relationship with C. difficile. Alternatively, Porphyromonadaceae in mice are the 
predominant Bacteroidales involved in resistance to colonization and growth. Using the 
microbiota structure data, we show the ability of a regression based model to accurately 
predict subsequent C. difficile colonization and growth levels 24 hours post challenge.  
 Understanding the interactions between C. difficile and the microbiota is crucial 
towards designing effective microbiota manipulation therapies. While FMTs are often 
successful in resolving CDI, a tailored multi-species probiotic approach would ensure 
transmission of an effective, safe, and compatible bacterial community. Given common 
themes among gut pathogen – microbiota – host interactions, these C. difficile studies 
may have broader applications for the microbiota in colonization resistance against 
other gastrointestinal pathogens. 
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CHAPTER II 
 
Microbiome data distinguishes patients with Clostridium difficile infection 
and non-C. difficile associated diarrhea from healthy controls 
 
 
Abstract 
Antibiotic usage is the most commonly cited risk factor for hospital-acquired 
Clostridium difficile infections (CDI).  The increased risk is due to disruption of the 
indigenous microbiome and a subsequent decrease in colonization resistance by the 
perturbed bacterial community; however, the specific changes in the microbiome that 
lead to increased risk are poorly understood.  We developed statistical models that 
incorporated microbiome data with clinical and demographic data to better understand 
why individuals develop CDI.  The 16S rRNA genes were sequenced from the feces of 
338 individuals, including cases, diarrheal controls, and non-diarrheal controls.  We 
modeled CDI and diarrheal status using multiple clinical variables including age, 
antibiotic use, antacid use, and other known risk factors using logit regression.  This 
base model was compared to models that incorporated microbiome data, using diversity 
metrics, community types, or specific bacterial populations, to identify characteristics of 
the microbiome associated with CDI susceptibility or resistance.  The addition of 
microbiome data significantly improved our ability to distinguish CDI status when 
comparing cases or diarrheal controls to non-diarrheal controls.  However, only when e 
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assigned samples to community types was it possible to differentiate cases from 
diarrheal controls.  Several bacterial species within the Ruminococcaceae, 
Lachnospiraceae, Bacteroides, and Porphyromonadaceae were largely absent in cases 
and highly associated with non-diarrheal controls.  The improved discriminatory ability of 
our microbiome-based models confirms that factors affecting the microbiome influence 
CDI. 
 
Introduction 
Since the discovery of penicillin in 1928, antibiotics have revolutionized health 
care, saving patients from life threatening infections such as bacteremia, bacterial 
meningitis, tuberculosis, and pneumonia.  It has recently been estimated that over 250 
million courses of antibiotics are prescribed to outpatients in the United States annually 
(1).  However besides eradicating the pathogen of interest, antibiotics also disturb 
members of the indigenous bacterial community of the gastrointestinal tract, i.e. the gut 
microbiome.  In hospitals, this disruption may result in Clostridium difficile infection 
(CDI), the leading nosocomial infectious disease in the United States.  Cases of CDI 
have more than doubled since 2001 with over 300,000 new diagnoses in 2009 (2). 
An intact microbiome is crucial for its role in providing colonization resistance 
against C. difficile.  Antibiotic use, proton pump inhibitors, and advancing age, which are 
all known to influence the composition of the gut microbiome, are all risk factors for CDI 
(3-8).  However, no one has developed a set of microbiome-based biomarkers for CDI 
to complement these risk factors.  Therefore, characterizing the differences in the 
microbiome of individuals with and without CDI is essential towards understanding the 
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changes within the microbiome associated with CDI.  This knowledge would also 
potentially lead to novel targeted therapies as the typical treatments of metronidazole 
and vancomycin feed the cycle of disrupting the gut microbiome.  For the estimated 
25% of cases of CDI-characterized recurrent infection, the most effective treatment has 
been fecal microbial transplant (FMT), which has a 92% success rate in limiting further 
recurrence (9).  The remarkable success of FMT, which restores the normal 
microbiome, underscores the importance of understanding the role of the microbiome in 
providing colonization resistance. 
Current microbiome-related studies use three general methods to characterize 
differences in the microbiome between groups of individuals.  First, the microbial 
community composition of an individual can be distilled into a single parameter (i.e. 
alpha diversity) to describe the community in terms of richness or diversity.  For 
instance, it has been shown that individuals with diarrhea tend to have a less diverse 
community composition than healthy individuals (10-11).  Unfortunately, such results do 
not lend themselves to subsequent mechanistic investigations and do not provide a 
therapeutic avenue since it is difficult to predict whether an antibiotic will increase or 
decrease an individual’s diversity.  Second, cross-community comparisons have been 
made (i.e. beta diversity) to relate the similarity of microbial communities between 
individuals (e.g. UniFrac, Bray-Curtis).  In humans, these metrics are useful in tracking 
an individual’s recovery from antibiotic therapy (6); however, they have had limited use 
in discriminating between treatment groups (e.g. 12).  Using beta diversity metrics, it is 
again difficult to develop a mechanistic understanding of the relationship between the 
community structure and disease or to provide a therapeutic avenue to change a 
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community structure.  Finally, in an approach similar to genome wide association 
studies, comparisons of the relative abundance of individual bacterial populations can 
be made between groups of individuals (10,13).  This approach does not account for the 
possibility that mixtures of populations can be protective or causative or that different 
mixtures can have the same phenotype in different individuals.  Here we propose a 
comprehensive modeling approach that incorporates clinical metadata to identify 
collections of bacteria that can be associated with health and disease.  A similar 
approach was recently used to model the microbiome to identify microbiome signatures 
of psoriasis; however, clinical data for the subjects was not included (14). 
To better understand how clinical and microbiome-based factors are associated 
with CDI, we characterized the gut microbiome of hospitalized individuals who 
developed diarrhea with and without CDI and healthy individuals from the broader 
community.  We used clinical and microbiome data to generate models of CDI status in 
order to differentiate between the three groups of subjects.  Addition of microbiome data 
to clinical-based models for CDI significantly improved the ability to differentiate these 
patient groups.  Using these models as tools, we identified bacteria with potential roles 
in colonization resistance against C. difficile, while controlling for clinically relevant risk 
factors. 
 
Results 
Patient sampling and base model framework 
Fecal samples were collected from 338 individuals.  Within this collection 183 
diarrheal stool samples were acquired from inpatients at the University of Michigan 
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Hospital including both subjects with CDI (n=94) and without CDI (n=89).  These 
samples were tested as positive or negative for C. difficile by the clinical microbiology 
lab at the hospital and subsequently confirmed through PCR using C. difficile specific 
16S rRNA primers (See Materials and Methods).  The remaining 155 non-diarrheal 
control stool samples were collected from individuals in the surrounding community.  
We collected a broad set of clinical data including risk factors for development of CDI 
from the subjects’ questionnaire responses and their medical records (Table 2.1).  As 
expected, antibiotic usage was more prevalent in CDI cases than individuals in either of 
the control groups (p<0.001).  Fluoroquinolones represented the most used at-risk 
antibiotic in hospitalized patients, followed by amoxicillin and cephalosporins.  
Interestingly, individuals that were CDI positive were more likely to have lived with a 
healthcare worker.  Together, these clinical data represented the framework for our 
base model.   
We used age, gender, race, antibiotics, antacids, vegetarian diet, surgery within 
the past 6 months, a history of CDI, residence with another person who had CDI, and 
residence with another person who works in the health care setting as explanatory 
variables for three logit models.  For each model, we evaluated their ability to 
discriminate group classification using the area under the receiver operator 
characteristic (ROC) curve (AUC) (15).  These curves look at the true positive rate, i.e. 
sensitivity, as it relates to the false positive rate, i.e. 1-specificity.  Using the full 
collection of explanatory variables we were interested in three comparisons.  The first 
comparison differentiated between the cases and the non-diarrheal controls 
(AUC=0.891).  The second differentiated between the cases and diarrheal controls 
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Characteristic Case (n=94) Diarrheal Control (n=89) 
Non-Diarrheal 
Control 
(n=155) 
P-value 
Sex     
Females, n (%) 53 (56.4%) 49 (55.1%) 102 (65.8%)  
Males, n (%) 41 (43.6%) 40 (44.9%) 53 (34.2%) 0.166 
Age     
Mean years (SD) 55.9 (18.3) 58.7 (14.9) 52.2 (21.5) 0.034 
Range years 18 - 89 18 - 85 19 - 88  
Race, n (%)    0.712 
White 84 (89.4%) 76 (85.4%) 129 (83.2%)  
Black 7 (7.4%) 9 (10.1%) 16 (10.3%)  
Other/Unknown 3 (3.2%) 4 (4.5%) 10 (6.5%)  
Weight, mean lbs (SD) 169.9 (56.9) 177.9 (54.5) 171.5 (47.3) 0.549 
Vegetarian, n (%) 2 (2.1%) 5 (5.6%) 8 (5.2%) 0.435 
Antibiotics <3 months, n (%) 72 (76.6%) 56 (62.9%) 21 (13.5%) <0.001 
Fluoroquinolone, n (%) 21 (22.3%) 17 (19.1%) 4 (2.6%) <0.001 
Amoxicillin, n (%) 10 (10.6%) 6 (6.7%) 7 (4.5%) 0.182 
Cephalosporin, n (%) 11 (11.7%) 3 (3.4%) 3 (1.9%) 0.004 
Clindamycin, n (%) 2 (2.1%) 0 5 (3.2%) 0.297 
Ampicillin, n (%) 1 (1.1%) 0 0 0.541 
Antacids <30 days, n (%) 20 (21.3%) 20 (22.5%) 11 (7.1%) 0.001 
Surgery <6 months, n (%) 48 (51.1%) 38 (42.7%) 14 (9.0%) <0.001 
History of C. difficile, n (%) 1 (1.1%) 2 (2.2%) 4 (2.6%) 0.793 
Reside with person with CDI, n (%) 1 (1.1%) 2 (2.2%) 1 (0.6%) 0.593 
Reside with healthcare worker, n (%) 25 (26.6%) 13 (14.6%) 17 (11.0%) 0.005 
 
TABLE 2.1 Demographic information for subjects in each experimental group 
 
 
  46 
(AUC=0.659).  The third differentiated between the diarrheal and non-diarrheal controls 
(AUC=0.849).  The base model for cases and diarrheal controls was the only 
comparison that was not significantly different than an empty model (i.e. a model 
without independent variables; p=0.189).  The AUC and 95% confidence intervals for all 
models are listed in Table 2.2.  These three models served as the base for our 
development of other logit models that incorporated microbiome-based data. 
 
Incorporation of diversity measures into logit models 
We first looked at the overall microbiome structural differences among the 
individuals in our study (Figure 2.1).  There were apparent structural differences 
between non-diarrheal control samples and hospital-acquired samples (cases and 
diarrheal controls).  These differences were statistically significant by analysis of 
molecular variance (AMOVA) (p<0.001).  The structure of cases and diarrheal controls 
were additionally significantly different from one another by AMOVA (p=0.02), although 
to a lesser degree.  In order to identify the differences between these experimental 
groups, we first looked at their levels of overall bacterial diversity.  Previous studies 
have shown that the bacterial diversity of subjects with initial and recurrent CDI is 
markedly lower than that of healthy subjects (10-11).  Measuring diversity using the 
inverse Simpson index, we found that hospital-acquired samples had a 2-fold lower 
diversity compared to the non-diarrheal controls, but were not significantly different from 
each other (Figure 2.2A).  A model based on the inverse Simpson index alone 
significantly differentiated non-diarrheal controls from either cases or diarrheal controls 
(Figure 2.2B-D); although this model performed no better than the base model alone.
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Contrasts:    AUC 95% CI P-value 
Base Model         
  Cases vs. Diarrheal Controls 0.659 0.580, 0.738 0.189* 
  Cases vs. Non-diarrheal Controls 0.891 0.849, 0.933 <0.0001* 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.849 0.795, 0.903 <0.0001* 
Inverse Simpson Alone       
  Cases vs. Diarrheal Controls 0.580 0.495, 0.665 0.554* 
  Cases vs. Non-diarrheal Controls 0.809 0.754, 0.865 <0.0001* 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.811 0.751, 0.871 <0.0001* 
Base + Inverse Simpson       
  Cases vs. Diarrheal Controls 0.665 0.586, 0.744 0.577** 
  Cases vs. Non-diarrheal Controls 0.922 0.889, 0.955 0.0072** 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.900 0.858, 0.942 0.0009** 
Community Types Alone       
  Cases vs. Diarrheal Controls 0.698 0.623, 0.773 0.0144* 
  Cases vs. Non-diarrheal Controls 0.896 0.855, 0.938 <0.0001* 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.828 0.774, 0.882 <0.0001* 
Base + Community Types       
  Cases vs. Diarrheal Controls 0.763 0.694, 0.831 0.0059** 
  Cases vs. Non-diarrheal Controls 0.957 0.934, 0.981 0.0002** 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.905 0.852, 0.958 0.0035** 
Specific OTUs Alone       
  Cases vs. Diarrheal Controls 0.696 0.619, 0.773 0.0934* 
  Cases vs. Non-diarrheal Controls 0.950 0.922, 0.978 <0.0001* 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.981 0.967, 0.995 <0.0001* 
Base + Specific OTUs       
  Cases vs. Diarrheal Controls 0.709 0.634, 0.784 0.0652**  
  Cases vs. Non-diarrheal Controls 0.985 0.973, 0.996 <0.0001** 
  Diarrheal Controls vs Non-diarrheal 
Controls 
0.983 0.971, 0.996 <0.0001** 
Base model included age, gender, race, antibiotics, antacids, surgery in last 6 months, history of C. difficile, 
vegetarian, residence with person with C. difficile, residence with healthcare worker. 
  * P-value for the difference in areas under ROC curves between an empty model versus the model listed. 
  ** P-value for the difference in areas under ROC curves for the Base Model versus the Base Model with  
    the microbiome data listed. 
 
TABLE 2.2 AUC comparisons of all models 
The AUC values and 95% confidence intervals were calculated for each model in our 
study.  Comparisons were made either between the listed model and an empty model 
(*) or between a combined base plus microbiome model and the base model (**), as 
indicated above.  Comparisons that were significant are shown as bold p-values. 
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FIGURE 2.1 Overall structural differences between experimental groups 
This non-metric multidimensional scaling (NMDS) plot was generated from the distance 
matrix of θYC values that assess structural differences between samples (40).  Gray 
represents non-diarrheal control samples, blue are diarrheal control samples, and red 
are case samples. 
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When we incorporated the inverse Simpson index into our base models, differentiation 
of cases from non-diarrheal controls was significantly improved (AUC=0.922, 
p=0.0072), and differentiation of diarrheal controls from non-diarrheal controls was also 
significantly improved (AUC=0.900, p=0.0009).  Cases and diarrheal controls were 
indistinguishable when we used models that incorporated the inverse Simpson index.  
We performed the same analysis using the Shannon diversity index and observed 
similar results.  These results indicate that although low diversity was a characteristic of 
CDI positive subjects, subjects with diarrhea had lower diversity than healthy 
outpatients. 
 
Incorporation of bacterial community types into logit models   
Next, we sought to determine whether a subject’s overall community composition 
differentiated CDI or diarrheal status.  We assigned the samples to a specified number 
of clusters (k=2-15) based on their similarity to other samples after removing the C. 
difficile OTU (OTU 19).  We selected 13 as the appropriate number of clusters (i.e. 
community types) as this resulted in the optimal AUC for the base model when we 
incorporated the subject’s community type.  These community types varied in the 
prevalence of CDI among individuals within each type (See Figure 2.3A, percent of 
case subjects).  Results from models using community types alone performed similarly 
to that of the base models (Figure 2.3B-D).  When the community type assignments 
were added to the base models, the AUCs significantly improved relative to the base 
models in all comparisons (Table 2.2). These results indicate that specific community 
types differentiated CDI status and suggest that certain community types may be
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FIGURE 2.2 Bacterial diversity distinguishes between subjects with and without 
diarrhea 
A.  Alpha diversity was measured using the inverse Simpson index.  Statistical analysis 
was performed using Dunn’s multiple comparison test.  **** Indicates p < 0.0001, n.s. 
indicates no significance, error bars represent +/- SEM. B-D. ROC curves and AUC 
values with 95% confidence intervals in parenthesis for each model comparing (B) case 
versus non-diarrheal control (NDC), (C) case versus diarrheal control (DC), and (D) 
diarrheal control versus non-diarrheal control.  Red represents the base model, blue 
represents the inverse Simpson model, and green represents the base + inverse 
Simpson model.  The straight line represents the null model.   
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more susceptible to colonization by C. difficile. 
To determine the taxonomic composition of each of these community types, we 
used the random forest feature selection algorithm to identify those taxa that were 
indicators for the different community types (Figure 2.3A).  There were 6 community 
types that were less prevalent among case individuals or diarrheal controls relative to 
the non-diarrheal controls (i.e. Types 12, 3, 9, 7, 13, and 11).  These 6 types had a 
higher relative abundance of OTUs belonging to the Bacteroides genus (OTUs 3, 4, 5, 
8), Alistipes (OTU 6), Prevotella (OTU 17), and Ruminococcaceae (OTU 7) than the 
other community types.  While the remaining 7 types (i.e. 1, 8, 10, 4, 6, 5, 2) were 
enriched in Enterobacteriaceae (OTU 1), Enterococcus (OTU 2), Blautia (OTU 11), and 
Lachnospiraceae (OTU 13).  There were 6 community types that were less prevalent 
among case individuals relative to the diarrheal controls (i.e. Types 6, 5, 2, 9, 7, and 
11).  These types could be further subdivided by the overall percentage of diarrheal 
controls within each type.  Types 6, 5, and 2 had a high percentage of diarrheal 
controls, while types 9, 7, and 11 had a low percentage of diarrheal controls (Table 2.3).  
Types 6, 5, and 2 were also low in non-diarrheal controls and lacked several OTUs 
found primarily in that group (Figure 2.3A).  Furthermore, types 2 and 6 were highly 
enriched in either Enterococcus or Enterobacteriaceae, respectively.  Types 9, 7, and 
11 also had a high proportion of non-diarrheal controls and were more abundant in 
OTUs found predominantly in the non-diarrheal control group.  These group-specific 
taxonomic features we have identified may be involved in susceptibility or resistance to 
CDI. 
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FIGURE 2.3 Specific community structure types significantly differentiate all 
population comparisons 
A.  Heat map showing the structural differences between each community type.  The 
top 3 rows show the percentage of individuals classified as a case, diarrheal control, or 
non-diarrheal control across each type.  The remaining rows show the relative 
abundance for OTUs identified using feature selection through random forest analysis.  
Although the relative abundance of C. difficile OTU 19 is shown, it was not considered 
in the formation of these community types.  Types are ordered by decreasing 
percentage of case individuals.  B-D. ROC curves and AUC values with 95% 
confidence intervals in parenthesis for each model comparing (B) case versus non-
diarrheal control, (C) case versus diarrheal control, and (D) diarrheal control versus 
non-diarrheal control.  Red represents the base model, blue represents the community 
types model, and green represents the base + community types model.  The straight 
line represents the null model. 
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Community 
Type 
#Diarrheal 
Controls 
#Non-
Diarrheal 
Controls 
#Cases Total n 
%Diarrheal 
Control 
%Non-
Diarrheal 
Control 
%Case 
1 6 0 14 20 30.0 0.0 70.0 
8 4 0 5 9 44.4 0.0 55.6 
10 5 1 7 13 38.5 7.7 53.8 
4 11 6 18 35 31.4 17.1 51.4 
6 11 0 9 20 55.0 0.0 45.0 
5 9 3 9 21 42.9 14.3 42.9 
2 19 0 7 26 73.1 0.0 26.9 
12 5 19 7 31 16.1 61.3 22.6 
3 2 34 10 46 4.3 73.9 21.7 
9 5 29 4 38 13.2 76.3 10.5 
7 6 16 2 24 25.0 66.7 8.3 
13 0 13 1 14 0.0 92.9 7.1 
11 6 34 1 41 14.6 82.9 2.4 
 
TABLE 2.3 Breakdown of the individuals in each community type 
All 338 subjects in the study were sorted into 13 community types using PAM (see 
Materials and Methods).  These 13 community types were ordered by the percentage of 
case individuals belonging to each type.  The number of diarrheal control, non-diarrheal 
control, and case subjects belonging to each community type are shown.   
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Incorporation of specific bacterial populations into logit models   
Having established that incorporation of a subject’s community type could better 
inform their CDI or diarrheal status than a diversity index, we attempted to determine 
whether more specific components of those community types could improve our 
models.  To accomplish this, we first identified those bacterial populations that were 
differentially represented in each of the three comparisons using LEfSe (Linear 
Discriminant Analysis Effect Size) (13); these analyses excluded C. difficile (OTU 19).  
Briefly, LEfSe uses the Kruskal-Wallis sum-rank test to identify taxonomic features that 
characterize the differences between our study groups and linear discriminant analysis 
to evaluate the effect size of each feature.  Within each comparison, the OTUs with the 
largest effect size in each group and comparison were included in the respective base 
model (see Figure 2.4A).   
Within the case versus non-diarrheal control comparison, 13 OTUs were 
significantly enriched in cases and 26 OTUs were significantly enriched in the non-
diarrheal controls (Figure 2.4A).  We selected 5 OTUs that were enriched in the cases 
and 5 that were enriched in the non-diarrheal controls (based on the most extreme 
differences) and included their relative abundance as independent variables in logit 
regression.  The relative abundance of these specific OTUs discriminated quite well 
between cases and non-diarrheal controls (AUC=0.950, Table 2.2).  Additionally the 
combined base-microbiome model significantly outperformed the base model 
(AUC=0.985, p<0.0001).  Subjects having CDI were significantly more likely to harbor 
Enterococcus (OTU 2), Lachnospiraceae (OTU 14), Erysipelotrichaceae (OTU 22), and 
significantly less likely to harbor Bacteroides (OTU 5) than non-diarrheal controls.
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FIGURE 2.4 Specific bacterial populations clearly differentiate non-diarrheal 
controls from subjects with CDI and non-CDI associated diarrhea 
A. LEfSe was used to compare cases and non-diarrheal controls, cases and diarrheal controls, and 
diarrheal controls and non-diarrheal controls.  Only the LDA scores of significant OTUs are shown.  
Grey boxes indicate not significant for given comparison. Number following bacterial name indicates 
OTU number.  Black boxes show the OTUs at the 0.25%-iles cutoff for each group that were chosen 
for inclusion in the microbiome models. DC, diarrheal control; NDC, non-diarrheal control.  B-D. 
ROC curves and AUC values with 95% confidence intervals in parenthesis for each model 
comparing (B) case versus non-diarrheal control, (C) case versus diarrheal control, and (D) diarrheal 
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control versus non-diarrheal control.  Red represents the base model, blue represents the specific 
OTUs model, and green represents the base + specific OTUs model.  The straight line represents 
the null model. 
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These results confirm the differences that were observed between the case and non-
diarrheal control enriched community types and highlight the populations that had the 
greatest contribution to the model. 
In the comparison of cases and diarrheal controls, no OTUs were significantly 
enriched in the diarrheal controls over the cases; however, we identified 6 OTUs that 
were significantly enriched in the cases (Figure 2.4A).  The relative abundances of 
these OTUs, when combined in a logit model (Figure 2.4C), did not significantly 
distinguish cases and diarrheal controls  (AUC=0.696, p=0.0934).  Furthermore, the 
base plus microbiome model was not significantly different from the base clinical model 
(AUC=0.709, p=0.0652).  Unlike the bacterial community type analysis, we were unable 
to identify specific structural differences that could distinguish between cases and 
diarrheal controls in this model.  These results confirm that overall microbiome structure 
was more discriminatory for patients with non-C. difficile associated and C. difficile 
associated diarrhea. 
Finally, in the comparison of diarrheal controls and non-diarrheal controls we 
identified 30 OTUs that were enriched in the non-diarrheal controls and 7 OTUs that 
were enriched in the diarrheal controls (Figure 2.4A).  Individuals with non-C. difficile 
associated diarrhea were more likely to have higher relative abundances of 
Enterobacteriaceae (OTU 1), Enterococcus (OTU 2), Erysipelotrichaceae (OTU 22), 
Streptococcus (OTU 10), and Blautia (OTU 11).  The non-diarrheal controls were more 
likely to have higher levels of several Bacteroides, Lachnospiraceae, and 
Ruminococcaceae OTUs.  These taxa are commonly associated with a healthy 
microbiome.  We used the 5 most enriched OTUs in each of the diarrheal control or the 
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non-diarrheal control group to create a logit model to differentiate between the two 
(Figure 2.4D).  These OTUs significantly differentiated the two control groups 
(AUC=0.981).  The inclusion of both clinical data and these OTUs provided 
considerable discrimination between the two groups as compared with the base model 
alone (AUC=0.983; p<0.0001).  These results indicate that there were significant 
changes to the microbiome when individuals had diarrhea.  
 
Discussion 
We found distinct differences in the microbiome of people with and without CDI 
as well as with and without diarrhea.  We developed classification models to 
differentiate whether individuals had C. difficile infection or non-C. difficile associated 
diarrhea based on clinical and microbiome data.  The microbiome was incorporated into 
these models using three approaches: diversity indices, community types, and defined 
bacterial subsets.  These approaches of representing the microbiome allowed us to 
describe the communities at varying levels of resolution.  When differentiating between 
the cases and diarrheal controls, incorporation of community types provided the only 
significant improvement in detection between these two groups of patients.  The inverse 
Simpson index and the utilization of specific OTUs did not differentiate these two 
groups.  For the comparisons of non-diarrheal controls to cases or diarrheal controls, 
inclusion of the microbiome data significantly enhanced our ability to differentiate the 
groups regardless of the approach we used to represent the microbiome.  The highest 
AUCs were observed when differentiating between hospitalized patients (either cases or 
diarrheal controls) and community residents (non-diarrheal controls), with AUCs 
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consistently greater than 0.9 when both clinical and microbiome data were considered.  
Specifically, representing the microbiome using specific sets of OTUs was the best 
approach for differentiating between hospitalized patients and community subjects.  
These findings stress the importance of not just one individual bacterial population or 
one metric of the community (e.g. diversity), but rather collections of bacterial 
populations or overall community types in detecting disease state.  They also suggest 
the presence of gut dysbiosis in patients with diarrhea.  These results demonstrate that 
knowledge of bacterial communities, not just single species, and in combination with 
clinical factors may be beneficial in generating epidemiological models of disease.   
Of our three comparisons, it was notable that the cases and diarrheal controls 
were the most similar.   First, the base model to differentiate the two groups was unable 
to perform significantly better than a null model (p=0.19).  Second, the inverse Simpson 
diversity index revealed similar levels in both groups (p=0.85).  Third, many community 
types characterized by high numbers of cases were also more likely to contain diarrheal 
controls than non-diarrheal controls, which tended to cluster separately from both 
diarrheal groups.  Finally, our OTU-based analysis did not identify any OTUs as being 
significantly enriched in the diarrheal controls relative to the cases.  Because of the 
similarity in community structure and in clinical risk factors for CDI, results suggest that 
many of the diarrheal control subjects may actually be susceptible to CDI and have not 
yet been exposed to C. difficile.  This implies that any perturbation resulting in diarrhea 
may also contribute to CDI.  This hypothesis is particularly relevant within a hospital 
setting where C. difficile spores are abundant and where there are numerous potential 
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causes of diarrhea including antibiotics (independent of CDI), infection, chemotherapy, 
and dietary changes. 
Our models that compared cases to non-diarrheal controls showed that 
Bacteroides, Lachnospiraceae, and Ruminococcaceae were enriched in controls and 
Enterococcus, Enterobacteriaceae, Erysipelotrichaceae, and some Lachnospiraceae 
were enriched in cases.  These results confirm previous related studies (10, 16-18).  
Members of the Lachnospiraceae and Ruminococcaceae are the primary butyrate-
producing bacteria in the human gastrointestinal tract.  Butyrate has been associated 
with inhibition of C. difficile growth in vitro (19), inflammation suppression, and the 
health of colonic cells.  Thus, butyrate as well as other short-chain fatty acids may 
represent one mechanism of colonization resistance.  Comparison of the sequences 
within our Bacteroides OTU (OTU 5), which was enriched in our non-diarrheal controls, 
to an annotated 16S rRNA gene database showed that they were highly similar to B. 
uniformis and B. acidifaciens.  B. uniformis was previously shown to ameliorate 
metabolic dysfunction caused by diet-induced obesity via changes in metabolic and 
immune responses (20).  Because obesity is a risk factor for CDI (21), it is possible that 
B. uniformis would also provide protection against infection by C. difficile.  B. 
acidifaciens was demonstrated to increase IgA+ B cells in the large intestine (22), which 
may also limit the growth of gastrointestinal pathogens such as C. difficile.  Overall, this 
shift in community structure is thought to be associated with a change in colonization 
resistance.  Murine models of CDI have observed that similar changes in community 
structure render normally resistant mice sensitive to colonization by C. difficile (23-24).  
Similarly, a mixture of 6 bacterial species that included a member of the Bacteroides 
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genus and a member of the Lachnospiraceae, which were both found significantly 
enriched in our non-diarrheal control population, was sufficient to clear C. difficile in a 
murine model of recurrent CDI (17).   
Microbiome analyses have revealed that bacterial populations are patchy across 
individuals and that there is no “core microbiome” (12).  This hinders one’s ability to 
consistently associate specific bacterial populations with disease.  Instead, others have 
developed the concept of community or enterotypes (25-27).  Although the biological 
interpretation of these clusters is controversial, our study demonstrates that categorizing 
individuals into community types or utilizing subsets of the bacterial community 
improves our ability to identify individuals that belong to specific disease states.  Similar 
approaches have been used to associate specific community types with the composition 
of one’s diet, obesity, inflammatory bowel disease, Crohn’s disease, Trichomonas 
vaginalis infection, vaginal pH, and ethnicity (25, 27-32); however, these studies have 
not combined the subject’s clinical information and community type to evaluate disease 
state. 
The models evaluated in this study reflect bacterial communities at a specific 
point in time for these three patient groups.  Thus we are limited in our ability to assess 
the contribution of the microbiome towards risk or prevention of CDI.  We also cannot 
determine the length of time that cases were colonized by C. difficile prior to sample 
collection.  The aim of this investigation was not to enhance CDI diagnostics, but to use 
a model-based framework to characterize features of the microbiome that are 
associated with CDI and health.  Our approach suggests that knowledge of an 
individual’s microbiome composition is useful in distinguishing disease from health.  
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However, prospective studies are needed to validate microbiome-based biomarkers of 
CDI risk.  Identification of such risk factors will only be possible if samples are collected 
before the development of CDI.  Furthermore, previous modeling has shown that 
albumin levels, white blood cell count, creatinine levels, age, and increased leukocyte 
count can be used to predict CDI severity and mortality (4, 9, 33).  It is possible that the 
incorporation of microbiome data could also be used to improve predictions of disease 
outcome.  However in the current investigation we did not collect sufficient CDI severity 
data to address this question.  As we have demonstrated in this study, there are distinct 
microbiome signatures that are associated with CDI.  Understanding which community-
wide changes are responsible for the loss in colonization resistance leading to CDI is 
critical for future risk models and therapeutics.  
 
Materials and Methods 
Sample collection and definitions.   
This study was approved by the University of Michigan Institutional Review 
Board.  The inpatient samples were collected from October 2010 to January 2012 at the 
University of Michigan Hospital, Ann Arbor, Michigan.  All enrollees granted patient 
consent.  Inpatient subjects were not pregnant, were suspected of having an initial 
episode of CDI (not recurrent CDI), and their stool sample was diarrheal.  Within 24 
hours of stool collection, these specimens were screened for C. difficile using the CDIFF 
QUIK CHEK COMPLETE® assay (TECHLAB, Blacksburg, VA).  This rapid membrane 
enzyme immunoassay tests for the presence of both the C. difficile antigen glutamate 
dehydrogenase (GDH) as well as the C. difficile toxin proteins A and B.  If this test 
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resulted in positive or negative result for both GDH and toxin proteins, the sample was 
classified as a case or as a diarrheal control, respectively.  If the test was positive only 
for GDH, a PCR screen for the C. difficile tcdB gene, which encodes the toxin B protein, 
was performed (34).  To confirm the results of the clinical lab, we additionally performed 
PCR on all inpatient samples using C. difficile specific 16S rRNA gene primers as 
described elsewhere (35).  Non-diarrheal, C. difficile negative samples were collected 
between January 2011 and January 2012 from individuals residing in the surrounding 
Ann Arbor area.  Subjects were excluded if they had any signs of diarrhea in the 
previous 7 days or were pregnant.  Once enrolled, individuals collected a stool sample 
using the provided home stool specimen kit. 
 
DNA sequencing and curation   
Total bacterial DNA was extracted from each stool sample using the PowerSoil®-
htp 96 Well Soil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA) on an EpMotion 
5075 liquid handling workstation (Eppendorf, Hamburg, Germany).  The V35 region of 
the 16S rRNA gene was amplified and sequenced using 454 GS FLX pyrosequencing 
platform and curated using mothur as previously described (36-37).  We sequenced and 
processed a mock community in parallel to the samples sequenced for this study (37).  
The observed error rate among the mock community samples was 0.009%.  Sequences 
were clustered into operational taxonomic units (OTUs) using a 3% distance cutoff (38).  
Taxonomic assignments were determined by using a naïve Bayesian classifier with the 
RDP training set with an 80% bootstrap confidence threshold.  To mitigate against the 
effects of uneven sampling, all samples were rarefied to 1450 sequences per sample 
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(37).  Among the samples with more than 1450 sequences, the number of sequences 
per sample varied from 1450 to 17120 with a mean of 6091 sequences/sample, a 
median of 5986, and a median absolute deviation of 1296.  The OTU corresponding to 
C. difficile (OTU19) was identified by checking the representative sequence against the 
nt NCBI database with blastn.  All 16S rRNA gene sequence data and the associated 
MIMARKS table are available at http://www.mothur.org/CDI_MicrobiomeModeling. 
 
Statistical analyses   
Initial statistical analyses were conducted to assess differences among the three 
study groups (C. difficile cases, diarrheal controls and non-diarrheal controls).  For 
continuous variables (e.g., age, weight) one-way analysis of variance was utilized.  For 
categorical variables, Pearson’s chi-squared test was calculated or Fisher’s exact test 
when expected cell frequencies were less than or equal to 5.  The principal intent of the 
analyses was to assess whether the addition of microbiome data added to case 
differentiation, and as such nested logit models were constructed with clinical data, with 
and without the incorporation of microbiome data.  We utilized three approaches to 
capture the biodiversity of the gut microbiome.  First, the inverse Simpson index was 
calculated for each sample and treated as a continuous variable in the models (39).  
Second, we assigned each sample to a different community type and used the type as 
categorical variables in the model.  These community types were identified by 
partitioning around medoids (PAM) of a Jensen-Shannon divergence distance matrix 
calculated from the microbiome data (27).  The randomForest package in R 
(http://cran.r-project.org/) with number of trees set to 1000 was used to differentiate the 
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composition of each cluster.  Third, we built models using the relative abundances of a 
subset of the OTUs observed across the individuals.  These OTUs were selected using 
LEfSe based on the comparisons of cases versus diarrheal controls, cases versus non-
diarrheal controls, and diarrheal controls versus non-diarrheal controls (13).  OTUs 
demonstrating the greatest differences (at a 0.25 percentile cutoff at both ends) were 
used as continuous variables in our logit models.  The 0.25 percentile cutoff was 
selected to restrict the number of significant OTUs in order to build the models and 
avoid over-fitting.  Differences between nested models were compared using the test for 
the equality of ROC areas (15).  Analyses were conducted in Stata/MP 12.1 and R 
version 3.0.1.  
 
Notes 
 This work was reprinted and modified with permission from Schubert A.M., 
Rogers M.A.M., Ring C., Mogle J., Petrosino J.P., Young V.B., Aronoff D.M., Schloss 
P.D. 2014. Microbiome data distinguishes patients with Clostridium difficile infection and 
non-C. difficile associated diarrhea from healthy controls. mBio. 5(3):e01021-14. 
  66 
References 
1. Hicks LA, Taylor TH, Hunkler RJ. 2013. U.S. outpatient antibiotic prescribing, 
2010. N Engl J Med. 368: 1461-1462. 
2. Lucado J, Gould C, Elixhauser A. 2012. Clostridium difficile Infections (CDI) in 
Hospital Stays, 2009. Healthcare Cost and Utilization Project.  http://www.hcup-
us.ahrq.gov/reports/statbriefs/sb124.jsp 
3. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. 2012. Epidemiology, 
diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect 
Ther. 10: 1405-1423. 
4. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, et al. 2012. Clostridium difficile 
Ribotype Does Not Predict Severe Infection. Clin Infect Dis. 55: 1661-1668. 
5. Yakob, L, Riley TV, Paterson DL, Clements ACA. 2013. Clostridium difficile 
exposure as an insidious source of infection in healthcare settings: an 
epidemiological model. BMC Infect Dis 13: 376. 
6. Dethlefsen L, Relman DA. 2010. Microbes and Health Sackler Colloquium: 
Incomplete recovery and individualized responses of the human distal gut 
microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA. 108: 
4554-4561. 
7. Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. 2014. Gastric 
microbiota is altered in oesophagitis and Barrett’s oesophagus and further 
modified by proton pump inhibitors. Environ Microbiol. 16: 2905-2914. 
  67 
8. Rea MC, O’Sullivan O, Shanahan F, O’Toole PW, Stanton C, et al. 2012. 
Clostridium difficile Carriage in Elderly Subjects and Associated Changes in the 
Intestinal Microbiota. J Clin Microbiol. 50: 867-875. 
9. Shivashankar R., Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, et 
al. 2013. Clinical Factors Associated With Development of Severe-Complicated 
Clostridium difficile Infection. Clin Gastroenterol Hepatol. 11: 1466-1471. 
10. Antharam VC, Li E, Ishmael A, Sharma A, Mai V, et al. 2013. Intestinal 
dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection 
and nosocomial diarrhea. J Clin Microbiol. 9:2884-2892. 
11. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, et al. 2008. 
Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-
associated diarrhea. J Infect Dis. 197: 435-438. 
12. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, et al. 
2009. A core gut microbiome in obese and lean twins. Nature. 457: 480-484. 
13. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, et al. 2011. 
Metagenomic biomarker discovery and explanation. Genome Biol. 12: R60. 
14. Statnikov A, Alekseyenko AV, Li Z, Henaff M, Perez-Perez GI, et al. 2013. 
Microbiomic signatures of psoriasis: feasibility and methodology comparison. Sci 
Rep. 3: 2620. 
15. DeLong ER, DeLong DM, Clarke-Pearson DL. 1988. Comparing the areas 
under two or more correlated receiver operating characteristic curves: a 
nonparametric approach. Biometrics: 837-845. 
  68 
16. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, et al. 2010. 
Comparative metagenomic study of alterations to the intestinal microbiota and 
risk of nosocomial Clostridum difficile-associated disease. J Infect Dis. 202: 
1877-1884. 
17. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, et al. 2012. Targeted 
restoration of the intestinal microbiota with a simple, defined bacteriotherapy 
resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8: 
e1002995. 
18. Vincent C, Stephens DA, Loo VG, Edens TJ, Behr MA, et al. 2013. 
Reductions in intestinal Clostridiales precede the development of nosocomial 
Clostridium difficile infection. Microbiome. 1: 18. 
19. Rolfe RD. 1984. Role of volatile fatty acids in colonization resistance to 
Clostridium difficile. Infect Immun. 45: 185-191. 
20. Cano PG, Santacruz A, Moya A, Sanz Y. 2012. Bacteroides uniformis CECT 
7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-
diet induced obesity. PLoS ONE. 7: e41079. 
21. Bishara J, Farah R, Mograbi J, Khalaila W, Abu-Elheja O, et al. 2013. Obesity 
as a risk factor for Clostridium difficile infection. Clin Infect Dis. 57: 489-493. 
22. Yanagibashi T, Hosono A, Oyama A, Tsuda M, Suzuki A, et al. 2013. IgA 
production in the large intestine is modulated by a different mechanism than in 
the small intestine: Bacteroides acidifaciens promotes IgA production in the large 
intestine by inducing germinal center formation and increasing the number of 
IgA+ B cells. Immunobiology. 218: 645-651. 
  69 
23. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, et al. 2011. 
Profound Alterations of Intestinal Microbiota following a Single Dose of 
Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced 
Colitis. Infect Immun. 80: 62-73. 
24. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, et al. 2011. 
The interplay between microbiome dynamics and pathogen dynamics in a murine 
model of Clostridium difficile Infection. Gut Microbes. 2: 145-158. 
25. Holmes I, Harris K, Quince C. 2012. Dirichlet multinomial mixtures: generative 
models for microbial metagenomics. PLoS ONE. 7: e30126. 
26. Koren O, Knights D, Gonzalez A, Waldron L, Segata N, et al. 2013. A guide to 
enterotypes across the human body: meta-analysis of microbial community 
structures in human microbiome datasets. PLoS Comput Biol. 9: e1002863. 
27. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al. 2011. 
Enterotypes of the human gut microbiome. Nature. 473: 174-180. 
28. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, et al. 2011. Linking long-
term dietary patterns with gut microbial enterotypes. Science. 334: 105-108. 
29. Quince C, Lundin EE, Andreasson AN, Greco D, Rafter J, et al. 2013. The 
impact of Crohn’s disease genes on healthy human gut microbiota: a pilot study. 
Gut. 62: 952-954. 
30. Brotman RM, Bradford LL, Conrad M, Gajer P, Ault K, et al. 2012. Association 
between Trichomonas vaginalis and vaginal bacterial community composition 
among reproductive-age women. Sex Transm Dis. 39: 807-812. 
  70 
31. Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UME, et al. 2012. 
Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 4: 
132ra152. 
32. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, et al. 2011. Vaginal 
microbiome of reproductive-age women. Proc Natl Acad Sci USA. 108 Suppl 1: 
4680-4687. 
33. Butt E, Foster JA, Keedwell E, Bell JE, Titball RW, et al. 2013. Derivation and 
validation of a simple, accurate and robust prediction rule for risk of mortality in 
patients with Clostridium difficile infection. BMC Infect Dis. 13: 316. 
34. Agaronov M, Karak SG, Maldonado Y, Tetreault J, Aslanzadeh J. 2012. 
Comparison of GeneXpert PCR to BD GeneOhm for detecting C. difficile toxin 
gene in GDH positive toxin negative samples. Ann Clin Lab Sci. 42: 397-400. 
35. Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. 2004. Development of 
an extensive set of 16S rDNA-targeted primers for quantification of pathogenic 
and indigenous bacteria in faecal samples by real-time PCR.  J Appl Microbiol. 
97: 1166-1177. 
36. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, et al. 2009. 
Introducing mothur: open-source, platform-independent, community-supported 
software for describing and comparing microbial communities. Appl Environl 
Microbiol. 75: 7537-7541. 
37. Schloss PD, Gevers D, Westcott SL. 2011. Reducing the effects of PCR 
amplification and sequencing artifacts on 16S rRNA-based studies. PLoS ONE. 
6: e27310. 
  71 
38. Schloss PD, Westcott SL. 2011. Assessing and improving methods used in 
operational taxonomic unit-based approaches for 16S rRNA gene sequence 
analysis. Appl Environl Microbiol. 77: 3219-3226. 
39. Magurran AE. 1988. Ecological diversity and its measurement. Princeton 
University Press, 534 Princeton, NJ. 
40. Yue JC, Clayton MK. 2005. A similarity measure based on species proportions. 
Commun Stat Theor M. 34: 2123-2131. 
 
  72 
 
 
CHAPTER III 
 
Antibiotic-induced alterations of the murine gut microbiota and 
subsequent effects on colonization resistance against Clostridium difficile 
 
 
Abstract 
Perturbations to the gut microbiota result in a loss of colonization resistance 
against gastrointestinal pathogens such as Clostridium difficile. Although C. difficile 
infection is commonly associated with antibiotic use, the precise alterations to the 
microbiota associated with this loss in function are unknown. We used a variety of 
antibiotic perturbations to generate a diverse array of gut microbiota structures, which 
were then challenged with C. difficile spores. Across these treatments we observed that 
C. difficile resistance was never attributable to a single organism, but rather it was the 
result of multiple microbiota members interacting in a context-dependent manner. Using 
relative abundance data, we built a machine learning regression model to predict the 
levels of C. difficile that were found 24 hours after challenging the perturbed 
communities. This model was able to explain 77.2% of the variation in the observed 
number of C. difficile per gram of feces. This model revealed important bacterial 
populations within the microbiota, which correlation analysis alone did not detect. 
Specifically, we observed that populations associated with the Porphyromonadaceae, 
Lachnospiraceae, Lactobacillus, and Alistipes were protective and populations 
  73 
associated with Escherichia and Streptococcus were associated with high levels of 
colonization. In addition, a population affiliated with Akkermansia indicated a strong 
context dependency on other members of the microbiota. Together, these results 
indicate that individual bacterial populations do not drive colonization resistance to C. 
difficile. Rather, multiple diverse assemblages act in concert to mediate colonization 
resistance. 
 
Introduction 
The microbiota, or the diverse community of microorganisms living in and on the 
body, has an integral role in deterring pathogen colonization and infection (1). This 
native protection by the microbiota from invasive pathogenic species is termed 
colonization resistance. It is well established that the gut bacterial microbiota is critical in 
the host's defense against the pathogen Clostridium difficile (2-4). Perturbations to this 
indigenous community often lead to a loss of resistance. This is especially important in 
many hospital settings where patients are not only exposed to various types and 
degrees of perturbations, such as antibiotics, diet changes, and chemotherapy, but they 
are also exposed to C. difficile spores from their environment (5). C. difficile infections 
(CDI) are the most reported hospital-acquired infection in the United States and are 
responsible for 14,000 deaths a year (6). 
It is not completely understood how different perturbations to the gut microbiota 
result in a loss of colonization resistance to C. difficile. There is a clear need to better 
understand the ecology of C. difficile and its interactions with members of the 
microbiota. In mouse models of CDI, the unperturbed, untreated murine microbiome is 
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completely resistant to C. difficile colonization. It was previously shown that C57Bl/6 
mice treated with cefoperazone (3, 7), tigecycline (8), clindamycin (9), or clindamycin in 
combination with a five antibiotic cocktail (2) had decreased colonization resistance. 
These studies suggest that a loss of Lachnospiraceae and Barnesiella and a bloom of 
Lactobacillaceae and Enterobacteriaceae are responsible for the loss of colonization 
resistance. These results are largely supported by human association studies (10, 11). 
We previously observed significant differences between the gut microbiota of 
hospitalized individuals with and without C. difficile and non-hospitalized controls (10). 
In addition, fecal microbiota transplants increase Bacteroidetes and decrease 
Proteobacteria levels in recipients, resulting in a successful restoration of colonization 
resistance in patients (12). Precisely how this occurs is not fully understood, but it 
emphasizes the importance of the gut microbiota in colonization resistance against C. 
difficile. 
Because the gut microbiota is a complex community we need tools that enable 
us to dissect the interactions within the community and with C. difficile. One approach is 
the use of mathematical models to identify associations between members of the 
microbiota and C. difficile. Mathematical models have been used to predict C. difficile 
(10, 13) and Citrobacter infection (14), colon cancer (15), and psoriasis (16) based on 
the composition of the gut microbiota. We similarly sought to identify the subset of the 
normal murine microbiota that are responsible for colonization resistance by using 
mathematical models to explain the relationship between members of the gut 
microbiota. 
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The purpose of this investigation was to expand our current knowledge of the 
effects of various perturbations on colonization resistance against C. difficile. Through 
the administration of different antibiotic classes, doses, and recovery times we altered 
the murine gut microbiota and challenged the communities with C. difficile spores to 
quantify differences in colonization resistance. We then used 16S rRNA gene 
sequencing to identify structural changes within the microbiota that would be predictive 
of colonization resistance. Using these data, we built a random forest regression model 
to predict C. difficile colonization levels. Through this analysis, we have identified 
groups of related bacteria that are associated with C. difficile colonization resistance. 
This model revealed that the interactions giving rise to colonization resistance were 
non-linear and context dependent. These findings show we can successfully apply 
modeling techniques to accurately predict the colonization resistance of a given 
microbiota. 
 
Results 
Antibiotics differentially alter the structure of the microbiota and their 
colonization resistance to C. difficile 
We selected a panel of seven antibiotics from six classes with the goal of 
differentially altering the microbiota and assessing their resistance to C. difficile 
colonization (Table 3.1). Following the cessation of antibiotics, each treatment group 
was given one day of recovery prior to challenge with C. difficile spores. One day post 
challenge we enumerated the density of C. difficile in the animals' feces. We observed 
reproducibly high levels of C. difficile colonization in mice treated with cefoperazone, 
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metronidazole, and streptomycin (Figures 3.1 and 3.2). We observed variable levels of 
C. difficile colonization in mice treated with ampicillin. None of the mice that received 
ciprofloxacin were colonized. In addition to administering ciprofloxacin by oral gavage, 
we provided ciprofloxacin by intraperitoneal injection (10 mg/mL). For both approaches 
we provided one or two days of recovery. Regardless of the method, the resulting 
communities were resistant to C. difficile colonization. Only one of six mice receiving 
vancomycin was colonized with C. difficile. We suspected that this was due to residual 
vancomycin repressing C. difficile growth. In fact, two days post C. difficile challenge, C. 
difficile bloomed in these mice to a median of 9.1x107 (interquartile range 7.6x107–
1.1x108) CFU/g feces. Furthermore, given two days of post-vancomycin recovery, there 
was no delay in C. difficile colonization to high levels, and on day one post challenge we 
observed a median of 3.0x107 (interquartile range 2.6x107–3.6x107, N=4) CFU/g feces. 
These results suggest that although vancomycin is not absorbed by the gut tissue, the 
absence of C. difficile in the remaining five vancomycin-treated mice may have been 
due to residual antibiotics lingering in the environment. Overall, the various antibiotic 
perturbations provided varying levels of colonization by C. difficile, which suggested that 
the resulting communities varied in their composition. 
 To test this hypothesis, we sequenced the 16S rRNA genes from the fecal 
communities of treated and untreated mice prior to C. difficile challenge to identify 
populations within the microbiota that conferred colonization resistance. All of the 
antibiotic treatments, except for the ciprofloxacin-treated mice (AMOVA, P=0.09), 
resulted in distinct and reproducible changes to the structure of the microbiota relative 
to the untreated animals (AMOVA, P<0.001). Comparisons of the microbiota between
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Antibiotic Administration Class Mechanism Target 
Ciprofloxacin Oral gavage, one time Fluoroquinolone Inhibits DNA gyrase Gram +/- 
Clindamycin Intraperitoneal injection, one time Lincosamide 
Inhibits protein 
synthesis Anaerobes 
Vancomycin Ad libitum in drinking water, five days Glycopeptide 
Inhibits 
peptidoglycan 
synthesis 
Gram + 
Streptomycin Ad libitum in drinking water, five days Aminoglycoside 
Inhibits protein 
synthesis Gram +/- 
Cefoperazone Ad libitum in drinking water, five days 
β-lactam: 
Cephalosporin 
Inhibits 
peptidoglycan 
synthesis 
Gram +/- 
Ampicillin Ad libitum in drinking water, five days β-lactam: Penicillin 
Inhibits 
peptidoglycan 
synthesis 
Gram +/- 
Metronidazole Ad libitum in drinking water, five days Nitromidazole 
Destabilizes 
bacterial DNA Anaerobes 
 
TABLE 3.1 Description of antibiotics used in the study 
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FIGURE 3.1 Antibiotic treatments result in significant alterations to the structure 
of the microbiota and variation in colonization resistance 
Bars indicate the median percent relative abundance of those selected OTUs from all 
treatment groups on the day of C. difficile challenge. Stars along the x-axis indicate 
those OTUs that were significantly different from untreated mice for that antibiotic 
treatment. The error bars indicate the interquartile range. The median level C. difficile 
colonization found 24 hours post microbiota sampling and the number of animals in the 
treatment group is indicated in the top right for each treatment with the interquartile 
range in parentheses. The concentration next to the name of the antibiotic indicates the 
dose of the antibiotic that was given to the animals. 
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FIGURE 3.2 Effect of antibiotic perturbations on phylum-level representation of 
communities on day of C. difficile challenge 
Bars depict the median relative abundance across mice within the treatment group and 
error bars indicate the interquartile range. 
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antibiotic classes indicated that their structures were significantly different from each 
other (AMOVA, P<0.03). The community structures of mice receiving beta-lactams (i.e. 
cefoperazone and ampicillin) were not significantly different from each other (AMOVA, 
P=0.37). These results indicate that perturbing the gut microbiota with antibiotics 
resulted in non-overlapping community structures that yielded significant variation in 
susceptibility to colonization when challenged with C. difficile. 
 
Reduced perturbations result in altered levels of colonization 
Based on the C. difficile colonization levels in our seven antibiotic treatments, we 
hypothesized that titrating the dose of antibiotics that the mice received would result in 
smaller perturbations to the microbiota. Consequently we expected a greater 
maintenance of resistance against C. difficile colonization in these titrated treatment 
groups. In addition to the previous treatments, we treated mice with lower 
concentrations of cefoperazone, streptomycin, and vancomycin (Figure 3.3 and 3.4). 
These antibiotics were selected because they are thought to target a broad spectrum of 
bacteria (i.e. cefoperazone), primarily Gram-negative (i.e. streptomycin), and Gram-
positive (i.e. vancomycin) bacteria. As expected in all mice receiving titrated doses of 
cefoperazone, C. difficile colonization levels decreased significantly (P<0.02; Figure 
3.3). Titrating the dose of cefoperazone in the animals' drinking water resulted in 
significant decreases in the relative abundance of an OTU associated with the genus 
Escherichia (OTU 3) and a number of rare OTUs. We also observed increases in the 
relative abundances of OTUs associated with the family Porphyromonadaceae (OTU 5, 
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10, 11, 13, and 21; Figure 3.3). Reducing the dose of streptomycin significantly reduced 
the colonization levels (P<0.01; Figure 3.3). Titrating the dose of streptomycin in the 
drinking water resulted in significant changes in the relative abundance of OTUs 
associated with the Porphyromonadaceae (OTUs 2, 5, 6, 10, and 11), Alistipes (OTU 
12), and Bacteroidales (OTU 17). In addition to its anti-Gram-positive activity, 
vancomycin was also selected because although the community was quite different 
from untreated mice, we observed high levels of C. difficile colonization in only one 
mouse. We anticipated that lower doses might result in a community structure that 
would result in colonization. In fact, the 0.3 and 0.1 mg/mL doses of vancomycin 
resulted in similarly high levels of C. difficile colonization (P=0.96). Seven OTUs were 
differentially represented across the three doses of vancomycin. Surprisingly, even 
though the colonization levels of C. difficile did not significantly differ between the mice 
receiving 0.1 and 0.3 mg/mL of vancomycin in their drinking water, four of the OTUs that 
had significantly different relative abundances were only found in the lower dose. Three 
of these were affiliated with members of the Porphyromonadaceae (OTUs 2, 5, and 6) 
and one was affiliated with a member of the genus Bacteroides (OTU 1). Two OTUs 
affiliated with the Akkermansia (OTU 6) and Lactobacillus (OTU 8) genera increased 
with increasing dose and a third OTU affiliated with Escherichia (OTU 4) had a mixed 
response to the dose level. These results suggest that the context in which specific 
members of the microbiota are found is important in determining the overall resistance 
to C. difficile. For example, the relationship between the Bacteroides (OTU 1) and C. 
difficile colonization was positive in streptomycin-treated mice and it was negative in 
cefoperazone-treated mice. In addition, cefoperazone and streptomycin-treated mice 
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had high levels of C. difficile although the former had significantly higher levels of 
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FIGURE 3.3 Titration of antibiotic perturbations results in altered community 
structures and C. difficile colonization resistance 
Bars indicate the median percent relative abundance of those selected OTUs from all 
treatment groups on the day of C. difficile challenge. Stars along the x-axis indicate 
those OTUs that varied significantly across doses of the same antibiotic. The error bars 
indicate the interquartile range. The median level C. difficile colonization found 24 hours 
post microbiota sampling is plotted on the right for each treatment with error bars 
indicating the interquartile range. The number of animals used in each treatment group 
is indicated in the legend, which depicts the doses of each antibiotic that were used. 
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FIGURE 3.4 Effect of titrated antibiotic treatments on phylum-level representation 
of communities on day of C. difficile challenge 
Bars depict the median relative abundance across mice within the treatment group and 
error bars indicate the interquartile range. 
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Escherichia (OTU 3), which were absent in the streptomycin-treated mice. Together, 
these results suggest that individual populations were not sufficient to consistently 
predict colonization resistance. In light of such results, resistance is likely a product of 
the overall composition of the community. 
 
Allowing recovery of the microbiota restores colonization resistance 
In the experiments we have described thus far, we allowed the gut microbiota to 
recover for 24 hours before challenging them with C. difficile. Several studies have 
demonstrated that perturbed communities can return to a "healthy" state in which 
resistance to C. difficile is restored (3, 8). To test the effect of recovery on colonization 
and gain greater insights into the populations that confer colonization resistance, we 
allowed the microbiota of the mice that received the full metronidazole and ampicillin 
treatment to recover for an additional five days (Figure 3.5 and Figure 3.6). Among the 
metronidazole-treated mice, those with extended recovery had a 1.8 x 106-fold 
reduction in colonization (P<0.001; Figure 3.5). In addition, 7 of the 14 mice given the 
longer recovery period had no detectable C. difficile 24 hours after challenge. We 
detected six OTUs that were differentially represented in the two sets of metronidazole-
treated mice (Figure 3.5). Most notable among these was a member of the Barnesiella 
(OTU 2) and the Escherichia (OTU 3). The relative abundance of this Barnesiella OTU 
increased with the delay, and the relative abundance of this Escherichia OTU 
decreased. Similar to the metronidazole-treated mice, the ampicillin-treated mice that 
were allowed to recover an additional five days before challenge had a significant 
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decrease in C. difficile colonization (P=0.03). As before, we observed a similar increase 
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FIGURE 3.5 Increasing the recovery time following antibiotic perturbation 
restores colonization resistance 
Bars indicate the median percent relative abundance of those selected OTUs from all 
treatment groups on the day of C. difficile challenge. Stars along the x-axis indicate 
those OTUs that varied significantly between those mice that were allowed 1 or 6 days 
of recovery. The error bars indicate the interquartile range. The median level C. difficile 
colonization found 24 hours post microbiota sampling is plotted on the right for each 
recovery period and antibiotic with error bars indicating the interquartile range. The 
number of mice used in each treatment group is indicated above the C. difficile 
colonization data. The dose of each antibiotic is indicated next to the name of the 
antibiotic. 
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FIGURE 3.6 Effect of recovery period following antibiotic treatments on phylum-
level representation of communities on day of C. difficile challenge 
Bars depict the median relative abundance across mice within the treatment group and 
error bars indicate the interquartile range. 
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and decrease in relative abundances for Barnesiella (OTU 2) and Escherichia (OTU 3). 
However untreated, fully resistant mice harbored significantly lower levels of Barnesiella 
(OTU 2). Rather, untreated mice had high levels of various Porphyromonadaceae OTUs 
(Figure 3.1). These findings further confirm the context-dependency of colonization 
resistance suggested by the results of our titration experiments. 
 
Correlation analysis reveals potentially protective bacteria 
To identify bacterial taxa that could be associated with resistance or susceptibility 
to C. difficile across the three sets of experiments, we measured the correlation 
between the relative abundance of each OTU on the day of inoculation with the level of 
C. difficile colonization 24 hours later (Figure 3.7). OTUs associated with providing 
resistance against C. difficile (N=22) outnumbered those with associated with 
susceptibility (N=9). The Porphyromonadaceae (ρaverage=-0.52, N=11 OTUs) were 
consistently associated with low levels of C. difficile colonization. Among the three 
Proteobacteria OTUs with a significant positive association with C. difficile colonization, 
the strongest was affiliated with the Escherichia (OTU 3; ρ=0.54). By performing an 
OTU-based analysis we were able to observe intra-family and genus differences in 
association with C. difficile colonization. For example, the Lachnospiraceae have been 
associated with protection against C. difficile. Although we observed three OTUs that 
were associated with low levels of C. difficile colonization, one OTU was associated with 
high levels of C. difficile. In addition we observed three significantly correlated 
Lactobacillus OTUs (family Lactobacillaceae), two of which were associated with low 
levels of C. difficile and one was associated with high levels. The broad taxonomic  
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FIGURE 3.7 Diverse taxonomic groups are associated with low levels of C. 
difficile colonization 
Spearman correlation coefficients were calculated using the relative abundance of 
OTUs found on the day that mice were challenged with C. difficile spores and the 
amount of C. difficile observed 24 hours later. Only significant correlations are 
presented. OTUs are grouped by the taxonomic family and the letters in the 
parentheses correspond to the phylum that the taxa belong to. B: Bacteroidetes, F: 
Firmicutes, P: Proteobacteria, A: Actinobacteria, T: Tenericutes. 
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representation of OTUs associated with low levels of C. difficile again suggests that a 
functionally diverse community is required to prevent the colonization C. difficile. 
 
The composition of the disturbed gut microbiota is predictive of C. difficile 
colonization levels 
These three sets of experiments demonstrated that in certain contexts individual 
OTUs could be associated with C. difficile colonization, but in other contexts those 
OTUs had the opposite or no association. This suggests that colonization is a 
phenotype that is driven by multiple populations that act independently and possibly in 
concert to resist colonization. Correlation-based analyses cannot predict these types of 
context dependencies because they do not take into account the non-linearity and 
statistical interactions between populations. Therefore, we used a regression-based 
random forest machine learning algorithm to predict the level of C. difficile colonization 
observed in the three sets of experiments using the composition of the microbiota at the 
time of challenge as predictor variables. The model explained 77.2% of the variation in 
the observed C. difficile colonization levels (Figure 3.8). When we only included the top 
12 OTUs based on the percent increase in the mean squared error when each OTU 
was removed, the resulting model explained 77.1% of the variation in the observed C. 
difficile colonization levels. The OTUs that were ranked as being the most important in 
defining the random forest model further validated the observations from the correlation-
based analysis (Figure 3.9). According to the random forest model, colonization  
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FIGURE 3.8 Random forest regression model predicts C. difficile colonization 
levels based on the structure of the microbiota 
The overall model explained 77.2% of the variation in the data. Each pane shows 
antibiotic treatment groups in color and the other points as gray circles. 
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FIGURE 3.9 The change in percent mean squared error when each OTU was 
removed from the random forest regression model 
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resistance was associated with members of the Porphyromonadaceae (OTU 15, 10, 6, 
18, and 11), Lachnospiraceae (OTU 25), Lactobacillus (OTU 23), Alistipes (OTU 12), 
and Turicibacter (OTU 9; Figure 3.10). A loss in these populations, concurrently with a 
gain of Escherichia (OTU 3) or Streptococcus (OTU 90), was associated with an 
increased susceptibility to infection (Figure 3.10). As we observed in the titration 
experiments, the relationship between Akkermansia (OTU 4) and C. difficile indicated 
that wide variation in the relative abundance of Akkermansia was associated with 
varying levels of C. difficile. There were varying abundances of Akkermansia in mice 
regardless of the level of C. difficile colonization. Finally, as indicated by the number of 
OTUs with relative abundances below the limit of detection, those mice could harbor 
varying levels of C. difficile. These observations bolster the hypothesis that colonization 
resistance is context dependent. 
 
Discussion 
Previous attempts to study the role of the gut microbiota in colonization 
resistance against C. difficile infection have utilized a single perturbation to the 
community. Here, we used seven antibiotics from six classes that were given to mice in 
varying doses and with varying post-antibiotic recovery periods. The result was a 
combination of 15 different perturbations and the non-perturbed microbiota, which 
allowed us to generate distinct community profiles that displayed varying susceptibility 
to C. difficile colonization. Our findings demonstrated that colonization resistance was 
not driven by individual populations, but by a consortium of organisms. Others have 
demonstrated that Barnesiella or Lachnospiraceae are partially protective against C.  
  95 
 
FIGURE 3.10 Relationship between OTU relative abundance and C. difficile 
colonization levels indicates non-linearity and context-dependency 
The 12 OTUs that resulted in the greatest change in percent mean squared error when 
removed from the random forest regression model are shown in each pane and 
together explain 77.1% of the variation in the data. The Spearman correlation value 
between that OTUs abundance and C. difficile levels are shown for each pane. The 
color and symbols represent the same antibiotic dose and recovery period as in Figure 
3.8. 
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difficile (9, 17). Although we observed similar results in a subset of our perturbations, by 
using a large number of perturbations, we were able to demonstrate that a varied 
collection of populations was important for complete colonization resistance. Thus 
colonization resistance can be described as an emergent property of the microbiome, in 
which individual bacterial populations integrated in a community contribute to the overall 
resistance to C. difficile (18). 
There is clear need for more efficient therapies for treatment of C. difficile 
infections in humans aimed at restoration of the microbiota. Current first line treatments 
of CDI include regimens of either metronidazole or vancomycin, which further perturb 
the microbiota. As such, relapse rates for CDI are typically around 25-30% (19). 
Interestingly, we observed that treatment with either antibiotic induced susceptibility to 
C. difficile in mice. This result has implications for understanding the causes of recurrent 
infections. Previous efforts to restore the microbiota and reestablish colonization 
resistance also support our findings. For instance, association of germ-free mice with a 
Lachnospiraceae isolate only reduced the level of C. difficile colonization by 10 to 100-
fold (17). Using conventional mice, mixtures of bacteria rather than individual 
populations have been shown to restore colonization resistance and mediate clearance 
of C. difficile (20, 21). Fecal transplants, which represent a diverse collection of bacterial 
populations, have been highly effective in treating humans with recurrent C. difficile (12, 
22, 23). By generating a diverse collection of communities that were challenged with C. 
difficile, we have identified a subset of populations using random forest modeling that 
could be used as a probiotic cocktail to provide colonization resistance. These would 
  97 
include members of the Porphyromonadaceae, Lachnospiraceae, Lactobacillus, and 
Alistipes. Several of these populations have been examined for their potential as a 
probiotic for preventing C. difficile infection. A 6-species cocktail, including isolates of 
Porphyromonadaceae, Lachnospiraceae, Lactobacillus, Coriobacteriaceae, 
Staphylococcus, and Enterococcus, successfully resolved CDI in mice (21). In humans, 
Lactobacillus-based probiotics have been co-administered with antibiotics to deter the 
onset of antibiotic-associated diarrhea (AAD) and C. difficile infection (21). A more 
diverse probiotic, which contained 33 bacterial species including Porphyromonadaceae, 
Lachnospiraceae, Ruminococcaceae, Eubacteriaceae, and Lactobacillus isolates, 
successfully restored colonization resistance in recurrent C. difficile infection and 
eliminated diarrhea up to 6 months post treatment (24). Given this evidence, we feel 
confident that an effective probiotic community could be designed based on our findings 
to recover colonization resistance against C. difficile. 
Random forest regression models allowed us to describe community resistance 
as a byproduct of an assemblage of bacterial populations rather than as individual 
populations. A correlation-based analysis was unable to identify populations that had a 
context dependent or non-linear association with C. difficile colonization. Although the 
murine and human microbiota do not fully overlap, our previous analysis of humans 
infected with C. difficile supports the populations that we associated with colonization 
(10). For instance, Escherichia was previously associated with infected individuals and 
Lachnospiraceae, Ruminococcaceae, and Alistipes were absent from infected 
individuals. The overlap between the results from the current study and past human 
studies along with the power of random forest models suggest that it should be possible 
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to model a patient’s risk of developing a C. difficile infection based on their gut 
microbiota composition at admission. Overall these findings demonstrate the 
significance of the microbiota as an interconnected bacterial community in assessing 
resistance to pathogen colonization. 
 
Materials and Methods 
Animal care 
We used 5-8 week old C57Bl/6 mice for all of our experiments. These mice were 
reared under SPF conditions within the animal facility at the University of Michigan. All 
animal-related protocols and experiments were approved by the University Committee 
on Use and Care of Animals at the University of Michigan and carried out in accordance 
with the approved guidelines. 
 
Antibiotic administration 
Mice were administered one of seven different antibiotics including 
cefoperazone, vancomycin, metronidazole, streptomycin, ciprofloxacin, ampicillin, and 
clindamycin (Table 3.1). The route of administration depended on the specific antibiotic. 
Cefoperazone (0.5, 0.3, or 0.1 mg/ml), vancomycin (0.625, 0.3, or 0.1 mg/ml), 
streptomycin (5, 0.5, or 0.1 mg/ml), metronidazole (0.5 mg/ml), and ampicillin (0.5 
mg/ml) were all administered in the mouse drinking water for 5 days. Ciprofloxacin (10 
mg/kg) was administered via oral gavage and clindamycin (10 mg/kg) was administered 
via intraperitoneal injection. Mice that did not receive antibiotics were used as negative 
controls for these experiments. 
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C. difficile preparation and challenge 
All antibiotic-treated mice were given 24 hours to recover with untreated drinking 
water prior to C. difficile challenge. C. difficile strain 630Δerm spores were used in all 
experiments. Spores were prepared from a single large batch whose concentration was 
determined within the week prior to each C. difficile challenge (25). Spores were stored 
long term at 4°C. On the day of challenge 103 C. difficile spores were administered to 
mice via oral gavage. Immediately following this challenge, the remaining C. difficile 
inoculum was diluted in a series and plated to confirm the correct dosage. 
 
Sample collection and plating 
Fecal samples were freshly collected for each mouse on the day of C. difficile 
challenge. On the day after the challenge another fecal sample was weighed and 
diluted under anaerobic conditions with anaerobic PBS. The number of colony forming 
units (CFU) were counted following 24 hours growth on TCCFA plates at 37°C under 
anaerobic conditions (26). 
 
DNA extraction and sequencing 
Total bacterial DNA was extracted from each stool sample collected prior to 
challenge using the MOBIO PowerSoil®-htp 96 Well Soil DNA Isolation Kit. We 
generated amplicons of the V4 region within the 16S rRNA gene and sequenced the 
fragments using an Illumina MiSeq as previously described (27). 
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Sequence curation 
These sequences were curated using mothur (v.1.35) as previously described 
(27, 28). Briefly, sequences were binned into operational taxonomic units (OTUs) using 
a 3% dissimilarity cutoff. Taxonomic assignments were determined by using a naïve 
Bayesian classifier with the Ribosomal Database Project (RDP) training set (version 10) 
requiring an 80% bootstrap confidence score (29). In parallel to the fecal samples, we 
also sequenced a mock community where we knew the true sequence of the 16S rRNA 
gene sequences. Analysis of the mock community data indicated that the error rate 
following our curation procedure was 0.02%. All 16S rRNA gene sequence data and 
metadata are available through the Sequence Read Archive under accession 
SRP057386. 
 
Statistical analysis and modeling 
Complete scripts for regenerating our analysis and this paper are available at the 
online repository for this study 
(https://github.com/SchlossLab/Schubert_AbxD01_mBio_2015). Comparisons between 
the antibiotic-treated communities were made by calculating dissimilarity matrices 
based on the metric of Yue and Clayton (30). To avoid biases due to uneven sampling, 
the dissimilarity matrices were calculated by rarefying the samples to 1,625 sequences 
per sample. We then used analysis of molecular variance (AMOVA) to test for 
differences in community structure using 10,000 permutations (31). OTU-based 
analyses were performed using R (v.3.1.2). After subsampling the OTU frequency data 
  101 
to 1,625 sequences per sample, OTUs were considered for analysis if their average 
relative abundance within any treatment group was at least 1% (N=38 OTUs). All OTU-
by-OTU comparisons were performed using the Kruskal-Wallis rank sum test followed 
by pairwise Wilcoxon rank sum tests. Comparison of log (base 10) transformed C. 
difficile CFU/g feces between experimental groups was calculated using the Kruskal-
Wallis rank sum test followed by pairwise Wilcoxon rank sum tests. Spearman rank 
correlation analysis was performed between OTU counts and C. difficile CFU/g feces. 
All P-values were corrected using a Benjamini and Hochberg adjustment with an 
experiment-wide Type I error rate of 0.05 (32). Random forest regression models were 
constructed using the randomForest R package using 10,000 trees (33). The regression 
was performed using the log (base 10) transformation of the number of CFU/g fecal 
material as the dependent variable and the 38 OTUs as predictor variables. 
 
Notes 
This work was submitted to MBio in April 2015. 
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CHAPTER IV 
 
Discussion 
 
 
The microbiota has been described as a “microbial organ” due to the integral 
nature of these collective microorganisms in normal host functioning (1). One of the 
critical functions of this pseudo organ in the gut is to prevent the establishment of and 
inhibit pathogens’ subversion of the host for its own gain. Both the host and resident 
microbial community have a common interest in preventing disruption and invasion of 
the gut habitat by pathogens such as C. difficile. To this end, the microbiota acts as the 
first line of defense against C. difficile. The work presented in this dissertation explored 
the characteristics of resistant and susceptible microbiotas against C. difficile 
colonization.  
 
Chapter Summary 
The work described in this dissertation examined the relationships between C. 
difficile and members of the gut microbiota in both humans and mice. Use of statistical 
models allowed us to verify the contribution of the microbiota in determining C. difficile 
infection status and in predicting C. difficile colonization levels. We identified several 
bacterial populations implicated in resistance or increased susceptibility to C. difficile. 
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Many of these key positive and negative bacteria overlap in both hosts at the family 
level. These bacteria are potential targets of therapeutic manipulation in order to restore 
balance and the healthy functions of the microbiota. 
 
Microbiota Markers of C. difficile Infections 
 In Chapter II, the microbiotas of hospitalized patients with and without CDI were 
characterized. These individuals all had diarrhea, but differed in their clinical testing for 
C. difficile-associated diarrhea. These two groups were further compared to the 
microbiotas of healthy individuals without diarrhea from the surrounding community. 
Using logit models to predict C. difficile diagnosis, we assessed the contribution of 
patient microbiota structure data to the performance of a base model incorporating 
patient epidemiological data alone. The goal of this study was not to improve CDI 
diagnostics, but rather determine what characteristics of the microbiota defined each 
group. Microbiota data for the three experimental groups were introduced into the model 
using three approaches: 1) the inverse Simpson index, a measure of beta diversity of 
the community, 2) categorical community types, defined through clustering patient 
microbiotas based on structural distances, 3) the relative abundances of a microbiota 
subset, identified based on their effect size in our linear determinant analyses (LDA).  
 Regardless of the method of microbiota incorporation used in distinguishing 
healthy controls from hospitalized individuals, all microbiota-inclusive models performed 
as well or significantly better than the base epidemiological model alone. This suggests 
that there are defining microbiota characteristics between these two populations. For 
instance, hospitalized individuals, regardless of CDI status, had lower microbiota 
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diversity compared with community controls. Hospitalized individuals had significant 
losses in the normally dominant Bacteroidetes and Firmicutes from the control group. 
These include Bacteroides, Ruminococcaceae, Alistipes, and Lachnospiraceae many of 
which have been observed in previous mouse and human studies (Table 1.1).  
 Overall the two hospitalized groups were the most similar with high levels of 
Enterobacteriaceae and Enterococcus. Microbial community types was the only method 
which significantly enhanced model performance compared with the base model in 
distinguishing these two groups. Few bacterial species actually distinguished CDI from 
non-CDI associated diarrhea as determined by LDA, but included other Clostridium 
species, an Erysipelotrichaceae, and a Blautia OTU. Low diversity is characteristic of 
patients with CDI, especially recurrent CDI (2, 3). Because low diversity is also seen in 
non-CDI associated hospital patients, that both groups had diarrhea is the more 
probable determinant of their diversity level. It is likely that a community with decreased 
diversity is advantageous for C. difficile colonization. Bacterial community diversity has 
been recognized as a key factor in resistance to pathogen invasion of soil habitats (4). 
Specifically, it is proposed that decreased diversity contributes to an advantage in the 
pathogen’s competitive ability for resources (4). Community diversity also contributes to 
functional redundancy within the community, which helps maintain functional stability 
and resistance to change (5, 6). Our data suggests that the non-CDI associated 
diarrhea patients may be susceptible CDI, and factors contributing to diarrhea may in 
turn shift the microbiota towards a decrease in colonization resistance. Our overall 
findings emphasize the importance of the microbiota in the context of a community in 
determining pathogen resistance levels.  
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 Often a major limitation in studying the human microbiota in disease is the lack of 
individuals’ healthy baseline state. Given the high degree of inter-individual variation 
between the gut microbiotas of humans, cross-sectional human investigations mask this 
variation at finer taxonomic levels. Murine models of CDI allow for controlled longitudinal 
experiments to examine the dynamics of the microbiota and C. difficile during 
colonization and infection. 
 
Murine CDI Models Confirm Human Associations 
In Chapter III, we used murine models of CDI to measure colonization resistance 
levels of antibiotic-manipulated microbiotas. By observing CDI in a mouse model we 
could determine key features of microbiota structures contributing to C. difficile 
resistance. Using a broad representation of antibiotic classes, as well as varying doses 
and post-antibiotic recovery time, we differentially perturbed the microbiota and 
examined its effects on C. difficile colonization. Across these perturbations, we 
observed that there was no single bacterial population that was responsible for 
colonization resistance. Rather, resistance to C. difficile is the product of multiple 
interactions within the community.  
Among the seven antibiotics were metronidazole and vancomycin, which are the 
first choice of antibiotics to treat CDI in humans. Using the highest dose of vancomycin, 
the subsequent day no C. difficile is detected. However by day 2 post challenge (day 3 
post antibiotic cessation) there was a huge bloom in C. difficile (average 8.5x107 CFU/g 
feces, data not shown). In titrated vancomycin treatment groups, this delay in C. difficile 
bloom was not detected, and C. difficile colonized to high levels (approximately 107 
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CFU/g feces), suggesting that residual vancomycin in the highest dose group inhibited 
C. difficile growth on day 1 post challenge. Interestingly, following either vancomycin or 
metronidazole the resulting bacterial communities are susceptible to C. difficile 
colonization. These results demonstrate the need for alternative first line CDI treatments 
with the goal of restoring microbiota balance.  
 We allow partial restoration of the microbiota by delaying C. difficile challenge 
following the termination of metronidazole treatment by five additional days. During that 
period, metronidazole treated microbiotas showed signs of recovery towards baseline 
(Figure 3.5 and 3.6). Following this extended recovery time, these mice harbored 
significantly lower C. difficile CFU/g feces 24 hours post infection. Similar experiments 
were performed with ampicillin, in which we also saw a decrease in C. difficile 
colonization following extended post-antibiotic recovery. Both metronidazole and 
ampicillin delay groups had significant decreases in Enterobacteriaceae and increases 
in Porphyromonadaceae. Several studies have looked at the required recovery time in 
humans following antibiotics to allow restoration of microbiota colonization resistance. 
The first month following antibiotic cessation is associated with an increased risk for 
CDI, which decreases over the next three months (7-9). These microbiota post-
perturbation dynamics differ based on antibiotic and dose (10-14). With recovery time, 
the diversity of the microbiota increases and colonization resistance is gradually 
restored as the structure returns to a healthy stable state (11, 13-15). Our delay 
experiments emphasize the importance of restoring balance to the microbiota for 
pathogen resistance. 
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 By applying a variety of antibiotic types and degrees of perturbations, we 
collected data on microbiota structures with a range of colonization resistance levels. 
We show that a regression-based random forest model built using these microbiota 
relative abundances accurately predicts C. difficile levels the subsequent day (Figure 
3.8). Species-level OTUs with the most contribution to the model’s accuracy corroborate 
the importance of several Bacteroidetes and Firmicutes previously associated with 
resistance against C. difficile in both mice and humans (Table 1.1, Figure 3.9). 
Interestingly, Porphyromonadaceae was found in healthy mice, whereas in Chapter II 
we show that Bacteroides were the predominant Bacteroidales population associated 
with health in humans. This suggests there are host-specific structures involved in 
colonization resistance.  
 Turicibacter and Akkermansia are among the top 12 OTUs contributing to 
accuracy of our model, and yet their correlations with subsequent C. difficile 
colonization levels are not significant. Turicibacter was largely found in microbiota of 
mice given 5 additional recovery days prior to C. difficile challenge, in which we 
observed decreased C. difficile colonization. Akkermansia significantly blooms in the 
microbiota of mice treated with vancomycin, which induced high levels of C. difficile 
colonization. Interestingly, across all antibiotic treatments this OTU was not correlated 
with subsequent C. difficile levels. Both the low dose streptomycin and cefoperazone 
treatments (0.1 mg/mL) also had high levels of Akkermansia but resulted in low C. 
difficile levels 24 hours later. These two groups with higher colonization resistance also 
had no Enterobacteriaceae (OTU 4) and little to no overall Proteobacteria. These 
findings suggest that colonization resistance is context dependent. Of note, 
  113 
Akkermansia is a known host mucin degrader. While C. difficile is able to utilize glycans 
in host mucin, it does not contain the necessary enzymes to free these resources (16). 
High levels of Akkermansia may contribute to available nutrients for C. difficile growth. 
Degradation of the mucus layer by high levels of Akkermansia contributes to increased 
inflammation and susceptibility to GI infection by Salmonella enterica Typhimurium (17). 
Increased inflammation is favorable for Enterobacteriaceae such as E. coli, which can 
utilize the nitrates generated during inflammation (18, 19). Thus, it is possible that the 
importance of Akkermansia or Turicibacter is in its interactions with other bacteria with 
stronger positive or negative relationships with C. difficile, which would account for the 
lack of direct correlation between these bacteria and C. difficile. 
The research presented in this dissertation outlines key bacterial groups 
implicated in C. difficile resistance. Use of statistical models based on bacterial 
abundances accurately predicts C. difficile’s ability to colonize, effectively measuring the 
level of colonization resistance of the microbiota. These findings have clinical 
applications in CDI risk assessment based on gut microbial markers. The protective 
bacterial groups identified in these studies should be further tested for their efficacy as 
probiotics that restore C. difficile resistance. 
 
Future Directions 
Expanding a Microbiota Model of CDI 
Mathematical modeling is a powerful tool for uncovering interactions among 
variables (20-22), predicting responses to perturbation (23-25), and assessing 
biomarkers and risk of disease (26, 27). Future studies expanding the degrees and 
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types of perturbations and their subsequent effects on colonization resistance will refine 
the model and identify a broadly encompassing model. Extending the titration studies in 
Chapter III, I propose modifying or adding titration groups to cover the entire range from 
no colonization to maximal C. difficile colonization for each antibiotic. These studies 
may indicate if an abundance threshold exists for protective bacteria, either collectively 
or for individual protective populations. Furthermore perturbations other than antibiotics 
will likely have unique effects on the microbiota, host, and subsequent susceptibility to 
C. difficile. In a hospital setting several factors can potentially affect patients’ microbiota 
structure, including diet (28, 29), an array of medications (e.g. antibiotics (10, 11, 13), 
proton pump inhibitors (30), or laxatives (31)), chemotherapy (32, 33), and comorbidities 
(34-36). Inclusion of this expansive dataset can help improve our model. Given the 
ability of models to accurately determine disease status and predict pathogen 
colonization, there may also be potential in using markers of the microbiota to assess 
risk for CDI and predict disease severity.  
 
Direct Assessment of Bacteria in Colonization Resistance 
 This dissertation has presented strong evidence for several bacteria in 
colonization resistance against C. difficile. Follow up studies should assess the direct 
contribution of these bacteria in germfree mice. In Chapter II, microbiota association 
studies in humans suggested the importance of Bacteroides, Ruminococcaceae, 
Alistipes, and Lachnospiraceae in C. difficile resistance. In Chapter III, controlled murine 
models of CDI support these findings in addition to highlighting Porphyromonadaceae’s 
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protective influence in mice. I hypothesize that effective tailored probiotic CDI 
treatments can be designed using various combinations of these bacteria. 
There is evidence for the success of probiotics in treating CDI. Used as a 
prophylactic concurrently with antibiotics, probiotics have been shown to significantly 
reduce the risk of antibiotic-associated diarrhea (relative risk = 0.61) and CDI (relative 
risk = 0.37) in a meta-analysis of 16 studies (37). A 33-species probiotic was tested for 
its ability to resolve recurrent CDI in two patients (38). These species were isolated from 
a healthy adult donor and screened to ensure sensitivity to a range of antibiotics. This 
community probiotic was designed to reflect bacterial abundances found in previously 
characterized healthy human guts. A 100mL treatment (estimated concentration=3.5 x 
109 colony-forming units/ml) successfully cleared these individuals of CDI and relieved 
their diarrhea, even with incidental antibiotic treatments in subsequent weeks. Day 2 
and week 2 post treatment, these patients had increases in Bacteroidaceae, 
Porphyromonadaceae, Bifidobacteriaceae, Lachnospiraceae, Clostridiales, and 
Verrucomicrobiaceae with reductions in Enterobacteriaceae. These results reflect the 
relationships observed in Chapters II and III of this dissertation.  
In the clindamycin-induced murine model of CDI, a probiotic community of six 
bacterial species successfully restores the microbiota and clears C. difficile (39). These 
were isolated from healthy feces passaged overnight to enrich for cultivable probiotic 
candidates. Three of the bacteria in their protective mix were identified in Chapters II 
and III as having protective roles, including an Anaerostipes sp. nov. (a 
Lachnospiraceae), a Bacteroidetes sp. nov. (a Porphyromonadaceae), and a 
Lactobacillus reuteri (a Lactobacillaceae). Only these three species of the six were 
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found in all mice on all days subsequent to treatment.  Interestingly, the 
Porphyromonadaceae isolate was present in the probiotic at 3% of total clones tested, 
which bloomed to as high as 26% by day 4 post treatment. The remaining three 
species, Enterococcus hirae, Staphylococcus warneri, and Enterorhabdus sp. nov., 
were present in low abundance or not at all 4-14 days post-treatment. Both 
Enterococcus and Staphylococcus were positively associated with C. difficile 
colonization in Chapter III, although this was not significant (data not shown). 
Enterococcus, however, was observed in Chapter II at high levels in hospitalized 
individuals, including CDI cases (Figure 2.4). The work presented in this dissertation 
provides new insights into the relationships between microbiota members and C. 
difficile, which will allow for more informed designs of community probiotics. 
To design and test these probiotics, these bacteria should ideally be isolated 
from mice to test their resistance against C. difficile in germfree mice. It has been 
demonstrated that proper immune function occurs in germfree mice only when 
transplanted with host-specific bacteria (40). However, commercially available strains 
can also be used for difficult species. Selecting from our pool of candidate protective 
bacteria, monocolonization studies can be used to assess the individual contribution of 
each bacterial species in resistance to C. difficile colonization (41). However, this is not 
the context in which these bacteria confer resistance under normal circumstances. 
Another approach would be to use conventional mouse models of CDI to test the 
efficacy of designed community probiotics. Using this system, we can test the ability of 
the probiotics to induce a shift in dysbiotic microbiotas towards health. I would 
administer small communities that reflect their normal proportion in the mouse 
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microbiota as performed previously (38), immediately following the cessation of 
antibiotics. These mice would then be challenged with C. difficile to test the resistance 
of the resultant community. In order to ensure establishment of probiotic species, 
probiotic boosts should also be tested for their contribution to increasing treatment 
effectiveness. Because we know how various antibiotics alter the community structure 
from Chapter III, we can test if the same probiotic combination works differently or 
similarly in all antibiotic-perturbed backgrounds. Given some of the differences in 
potentially protective bacteria between mice and humans, similar studies can be 
performed using bioreactors seeded by human intestinal microbiota. This research 
could lead towards a better understanding of microbiota dynamics and lead towards 
methodologies in personalized probiotics.  
 
The Microbiota’s Role in “Infection” Resistance 
 Given the microbiota’s heavy hand in resisting C. difficile colonization, it is likely 
that the gut microbiota also plays a role in limiting C. difficile’s infection. The pathology 
observed during CDI is driven by C. difficile’s two primary toxins, A and B. I hypothesize 
that the microbiota contributes to infection resistance against C. difficile by negatively 
regulating toxin production. Several environmental signals have been shown to regulate 
toxin expression and production. Cysteine, proline, an amino acid mixture, lactic acid, 
butanol, and biotin have demonstrated negative effects on toxin expression and 
production (42-47). Recently it has been demonstrated that a thiolactone quorum 
signaling peptide regulates C. difficile toxin production. Accumulation of thiolactone 
produced by C. difficile stimulates toxin production. Given the microbiota’s influence on 
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gut environmental signals, it may be possible for microbiota members to interrupt or 
block this pathway.  
We know that using the cefoperazone-induced murine model of CDI, C. difficile 
strain VPI 10463 begins producing its toxins between 18-24 hours post infection (48). 
To test the effect of other bacteria on toxin production, I propose administering the 
individual or small community probiotics examined above for their contribution to 
colonization resistance. These would be orally gavaged at 18 hours post infection, 
which is prior to the expected appearance of toxin in the cecum, colon, and stool (48). 
At 24 hours post infection, the toxin levels in these sites would be quantified. Because 
the microbiota has a known role in mediating pathogen clearance in Salmonella enterica 
serovar Typhimurium infections (49), quantifying C. difficile levels will distinguish 
decreases in toxin induced by probiotics from decreases simply due to pathogen 
clearance. Timing of treatment may be important as well. It could be possible the 
probiotic should be administered in an earlier window to allow potential changes to 
occur before the expected onset of toxin production and sporulation. Healthy mouse 
cecal or colon content should be included as a positive control group in limiting toxin. 
The influence of environmental nutrients on both C. difficile’s growth, toxin production 
gives importance to the microbiota’s effect on available resources. This highlights the 
host-protective abilities of the microbiota throughout C. difficile’s colonization and 
infection process.  
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Ecological Model of C. difficile Colonization 
 Across our characterization of susceptible and resistant microbiotas in both mice 
and humans, several common factors led us to the ecological model in Figure 4.1. 
Upon an external perturbation, depending on the type and magnitude, the microbiota is 
altered to a certain degree. If this perturbation is significant, it can lead to a loss in 
diversity and contribute to overall instability of the microbiota. The structure of the 
bacterial community in a susceptible state in both mice and humans is associated with 
increases in various Proteobacteria, notably Escherichia and Pseudomonas, as well as 
Enterococcus, and members of the Lactobacillaceae. We suspect that Akkermansia’s 
contribution to C. difficile colonization is context-dependent on the presence of other 
bacteria. For example, in the presence of Escherichia, Akkermansia may aid in 
colonization of C. difficile by providing mucin-stored nutrients and subsequently inducing 
increases in inflammation. This can further support the growth of inflammatory bacteria, 
including E. coli. These bacteria not only have decreased competitive ability against C. 
difficile, but they also potentially contribute to creating an environment suitable for 
colonization and growth. 
 Less severe perturbations to the microbiota may alter the community structure 
but not induce dramatic shifts from the healthy baseline community or sufficiently 
decrease overall diversity. In these microbiota structures we observe higher levels of 
colonization resistance against C. difficile. These communities are characterized by high 
levels of Bacteroidetes overall and Firmicutes, specifically various Lachnospiraceae 
populations, Ruminococcaceae, and members of the Lactobacillaceae. Different 
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FIGURE 4.1 Ecological model of C. difficile colonization 
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consortia of these bacteria can be protective against C. difficile, and together contribute 
to the overall level of colonization resistance against this pathogen. 
 
Final Conclusions 
The gut microbiota plays a crucial role in colonization resistance against C. 
difficile. The findings of this work through both microbiota perturbation studies and 
mathematical modeling in mice and humans define a collection of bacterial populations 
from which to efficiently design probiotic therapies for CDI. Traditional antibiotic 
therapeutics eliminate C. difficile but leave collateral damage to the gut microbiota. C. 
difficile treatments aimed at restoration of a healthy-like microbiota, such as FMTs and 
probiotic cocktails, not only help mediate clearance of C. difficile, but also reestablish 
colonization resistance against future infection. Furthermore, this work could lead to 
better risk assessment for CDI in health care-associated settings. Patients at high risk 
may be given probiotics to prevent CDI altogether. Given the high degree of inter-
individual variation among healthy microbiotas, it may also be beneficial to personalize 
treatments based on an individual’s particular microbial needs. This work enhances our 
understanding of key bacterial populations involved in resistance or susceptibility to C. 
difficile, making personalized microbiota treatments against C. difficile and potentially 
other gastrointestinal pathogens a real possibility. 
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